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ABSTRACT
Radioreceptor assay and radioimmunoassay of selected 
benzodiazepines in urine samples from racing greyhounds.
Radioreceptor assay is a quick and relatively 
simple analytical method which can discriminate between 
classes of drugs with a high degree of specificity. As it 
is receptors which interact and "detect" the drugs, the 
particular class of drugs detected is dependant on the 
radiolabelled ligand which is displaced from the 
receptor. This eliminates the need to obtain a pure 
preparation of one particular type of receptor which 
contrasts with radioimmunoassay. With this method the 
antibodies have to be raised against a specific drug and 
then purified in order that crossreactivity with drugs 
from other pharmacological classes does not occur. Also 
radioreceptor assay will only detect the pharmacologically 
active compounds in the biological sample. This is 
advantageous as only they will be acting in the body to 
cause an effect, so only they need to be measured.
Prior to the analysis of greyhound urine samples, 
various aspects of the receptor assay were determined to 
ensure optimum results were obtained under an established 
set of conditions. Rat brain tissue was centrifuged in 
order to isolate the synaptosomal fraction containing the 
benzodiazepine receptors. The protein content of this 
fraction was estimated together with determination of the
- 2 -
actual number of receptors and their affinity for 
benzodiazepines. As the brain tissue was collected in 
batches and stored until required, the length of time it
could be kept at -20°C was determined together with the 
length of time prepared synaptosomal fractions could be 
stored under similar conditions.
The limits for the incubation period which enabled 
enough time for an equilibrium to be established between 
the benzodiazepine/radiolabelled benzodiazepine and the 
receptor were determined. These also allowed for the 
separation of large numbers of samples before disruption 
occurs naturally. Separation of bound and free 
radioligand was achieved by filtration. The filters were 
washed with sufficient assay buffer to minimise the 
non-specific binding whilst maintaining an almost 
instantaneous separation time. Radioreceptor assay of a 
variety of benzodiazepines, and their pharmacologically 
active metabolites, was carried out to assess the affinity 
of each one for the benzodiazepine receptor and therefore 
enabling their potency to be calculated. The very 
specific nature of the benzodiazepine-radioreceptor assay 
for benzodiazepines was tested by assaying a wide variety 
of non-benzodiazepines. Relatively high concentrations of 
these other drugs were used, compared to the diazepam 
standards, to increase the possibility of cross reaction 
with the benzodiazepine receptor.
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Once the experimental laboratory conditions had 
been established, a pilot study was carried out with the 
greyhounds to uncover any practical problems relating to
oral dosing and sample collection. This study also
allowed the laboratory procedures to be tested with actual 
greyhound urine samples containing diazepam. The major 
studies were carried out with triazolam and flunitrazepam, 
both short acting benzodiazepines. They both have
half-lives of only 2 to 3 hours in dogs and consequently
can only be detected in samples taken within a few hours 
of dosing. Also the concentration of drug present in each 
sample is less as triazolam and flunitrazepam are more 
potent than diazepam so lower doses are required to obtain 
a similar effect.
To increase the sample content of the amount of 
benzodiazepines and their metabolites which can be 
detected by radioreceptor assay, the urine underwent mild 
hydrolysis with J3-glucuronidase. This releases the 
metabolites from the glucuronide conjugate. By increasing 
the amount of pharmacologically active metabolites in the 
sample this serves to increase the sensitivity of the 
assay. In order to increase the sensitivity of the 
receptor assay even more, the samples were extracted with 
a variety of organic solvents. However the increase in 
assay time due to the inclusion of this extra step was not 
balanced by the increase in detection efficiency. 
Therefore the laboratory protocol to assay the samples 
included centrifugation of samples, to deposit any
- 4 -
particulate matter, rather than a full extraction 
procedure.
In order to confirm the presence of benzodiazepines 
in the urine samples, they were also analysed by 
radioimmunoassay, both before and after hydrolysis. The 
statistical comparison of the receptor assay and the 
radioimmunoassay results demonstrated the relative 
non-specificity of the benzodiazepine antibody used in RIA 
compared to the relative high specificity of the 
benzodiazepine receptor. The differing affinities of 
triazolam and flunitrazepam metabolites for the receptor 
had been previously determined and as the proportion in 
which they are excreted is known from the literature, it 
was possible to re-calculate the receptor assay results. 
Using only the increase in benzodiazepines detected after 
hydrolysis, accurate pharmacokinetic data could be 
obtained. As only a single oral dose was given with only 
serial urine samples collected, such data is limited to 
the calculation of the elimination rate constants and the 
half-lives of triazolam and flunitrazepam in greyhounds. 
Re-assay of triazolam urine samples after they had been 
stored at -20°C for 12 months gave results which were 
statistically compared to previous results from the assay 
of samples within two days of collection. This was to 
determine the stability of the samples under such 
conditions and has implications in cases where samples 
cannot be analysed on receipt and have to be stored for
some time.
CHAPTER ONE
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1:1 Radioreceptor Assays
Radioreceptor assays (RRA) were introduced in 1970
and are analogous to radioimmunoassay (RIA) as they are
simple, quick and easy to carry out. Requiring only a
basic scintillation counter they are a sensitive and
relatively cheap way of screening samples for groups of
drugs. Assays have been developed for most
pharmacological classes of drugs, neurotransmitters and
hormones. All follow the same principles usually
requiring no more than an appropriate radioligand and
range of standards to detect a wide variety of drugs [1,
2]. The receptor (R) source can be the same in all cases,
homogenised brain tissue, as the majority of drug
receptors can be found there. Specialized tissue is used
in some cases such as insulin [3] where insulin free
125
plasma is the receptor source and [ I j m s u l m  the 
radioligand. A variety of ligands for RRA of different 
classes of drugs and hormones are listed in table 1:1.
Table 1:1
- 6 -
Radioligands Required for the Radioreceptor 
Assay of Different Pharmacological Classes of 
D rugs.
Class of 
drug
Radioligand Reference
BZa 3[ H]diazepam 4,5.6.7,8
[3H]FNZ 9,10,11,12,13,14
Opioids
3
[ H]naloxone 15,16,17,18,
[3H]fentanyl 19
Neuroleptics [3H]haloperidol 20,21,
J3-adrenergic [3H]dihydro- 22,23.24,25,26
agonists alprenolol
anti­ [3H]QNBb 27,28
depressants
3 . .[ H] lmipramme 29 . 30
c
anticons [3H]phenytoin 31
hGHd [3H]hGH 32,33
Insulin [125IJ insulin 3,34
ANP0
125 [ I ] A N P 35,36
a = Benzodiazepine 
k = [3H]quinuclidinyl benzilate 
c = Anticonvulsants 
d = Human growth hormone 
e = Anti naturitic peptide
The value of the r r a  is that it is specific for the 
pharmacological class of drugs under investigation. The 
BZ-RRA has been tested against over 100 non-BZ from 22
distinct pharmacological groups and 14 possible 
neurotransmitters. None had any affinity for BZ-R at
levels below 0.1 mM [4], where as benzodiazepines could be
detected at levels down to 20-50nM. This specificity 
together with the RRA ability to detect only 
pharmacologically active drugs and metabolites gives it an 
advantage over conventional RIA. RIA is less specific as 
antibodies can cross react with other drugs, and there is 
the time interval (months) required in order to raise and 
purify suitable antibodies. With RRA little time is
wasted preparing a sample of homogenised brain tissue and 
finding an appropriate radioligand.
As with every new analytical method, its 
effectiveness has to be established and with RRA this was 
achieved by analysing the same samples by gas liquid 
chromatography (GLC) and RRA [9,10,12]. When the levels 
were quantified the correletion between the two sets was
very good (r = 0.96) [11].
Now RRA has been established as a method it has
been used in- clinical trials to determine benzodiazepine 
levels in plasma, serum and cerebrospinal fluid [6,8,13].
- 8 -
Its use as an analytical tool to study BZ-R and 
their interaction with new BZ-type compounds has greatly 
increased over the last few years. it can be used with 
equal efficiency with in vitro [37, 38, 39] and j^ n vivo 
[40,41,42,43,44] studies such as investigations into the 
way benzodiazepines and ethanol interact to depress the 
central nervous system. [45,46,47,48,49,50]. RRA of 
benzodiazepines can be used in combination with 
psychological tests for stress to assess the potential of 
a new BZ-type compound as an antianxiety agent [51,52] and 
anticonvulsant agent [46,53,54,55,56,57,58,59,60].
1:2 Benzodiazepines
Benzodiazepines come under the heading of 
tranquillisers as they are capable of calming a patient 
without producing hypnosis. As their main use is to treat 
anxiety, agitation and tension they are classified as 
minor tranquillisers [61,62]. These drugs are widely 
prescribed with twice as many women taking them as men
[63]. Diazepam (Valium) and chlordiazepoxide (Librium)
were first introduced in the 1960's to replace 
barbiturates as sleeping pills and sedatives. They had
fewer side effects and there is less chance of overdosing 
at high levels [64]. These benzodiazepines are long
acting and may cause a 'hangover effect' due to the 
relativly slow elimination from the blood [65,66,67,68].
- 9 -
Short acting benzodiazepines, such as triazolam (Halcion), 
and medium acting benzodiazepines, such as flunitrazepam 
(Rohypnol), have been developed which are eliminated from 
the blood within a few hours, thus fewer side effects are 
experienced [69,70,71,72].
Benzodiazepines are prescription only medicines and 
are controlled under class C of the Misuse of Drugs Act, 
1971, thus it is illegal to supply them, but not illegal 
to possess them without a prescription. Due to their wide 
availability they are open to abuse and the possibility 
they may be used to dope sporting animals, such as 
greyhounds, has to be considered. Therefore ways of 
detecting the various benzodiazepines in urine samples at 
very low levels, ng/ml, have to be developed.
As with any accurate analytical method, the 
presence of an endogenous form of the drug under 
investigation has to be considered, for example, opioids 
and opiate peptides (B-endorphins) [73,74,75]. Up to
the last few years no evidence for an endogenous BZ-type 
compound was available, but recently information from 
e 1ectrophysica1 studies and those involving monoclonal 
antibodies have indicated the presence of such a peptide. 
When purified it was found to be a low molecular weight 
protein and preliminary results show it to have a similar 
molecular structure to N-desmethyl diazepam
[76,77,78,79,80].
-  10 -
Monoclonal antibodies have detected BZ-like 
compounds, similar to N-desmethly diazepam, in mammalian
brain tissue and cow's milk [81]. A dietary source 
appears to be the most likely possibility as synthesis of 
a benzodiazepaine-1 ike structure, a heterocyclic ring with 
a chloride atom attatched, is highly unlikely. Some fungi 
such as Penici11ium eyelopium are capable of synthesising
such compounds and may prove to be the source by acting as
contaminants of food stuffs. Lorazepam - a dichloro 
compound has been found in drug free plasma, again this 
was attributed to a dietary source [82]. Investigations 
into a possible dietary source - wheat and potatoes,
revealed trace amounts of pharmacologically active 
benzodiazepines [83,84], with similar structures to 
diazepam.
Recently triazolam has become more widely available
and as it is excreted from the body within a few hours via
the urine, bile and faeces, sensitive methods are required
to detect low concentrations. This is especially true for
racetrack samples where doping may have taken place 3-4
hours prior to examination. The disposition of triazolam
14
in dogs has been previously studied with [ C]triazolam 
to establish its excretion profile and its metabolic
products [85,86,87].
-  11 -
Triazolam plasma levels peak 0.5hr after oral
dosing, decreasing by first order kinetics with a tx
%
of 0.85 hours. Highest levels of parent compound are 
reached 1 hour after dosing followed by a rapid decrease 
in concentration. A plateau period occurs 4-5 hours after 
oral dosing where plasma levels of triazolam and its 
metabolites remain constant for a 6 hour period before 
continuing to decrease at a slower rate - t.. 14.5
72
hours. This plateau period is possibly due to
redistribution of the protein bound triazolam and/or 
enterohepatic circulation. The major metabolites in dog 
urine are 1'-hydroxymethyl triazolam, conjugated 
1 1-hydroxymethyl triazolam and conjugated 4-hydroxy 
triazolam. The conjugate in both cases being the 
glucuronide.
Triazolam has been found to affect the mammalian 
circadian clock [88], though information is scarce in this 
area. It is thought to act at receptor sites in the eyes 
and pineal gland, the latter being proposed as the 
organisation centre for circadian rhythm. Rol5-1788 was 
found to block the phase shifting effect of triazolam thus 
having the potential to be used as a tool to study such 
inbuilt biological rhythms.
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The pharmacokinetics of flunitrazepam - a medium 
acting benzodiazepine, have also been studied in dog with 
urine and plasma samples [89,90,]. Following oral dosing 
it is rapidly metabolised, with a t of 2 hours, and
72
eliminated via the urine as the metabolites N-desmethyl 
flunitrazepam and 7-amino flunitrazepam. Both are
excreted as the glucuronide [91],
1:3 Benzodiazepine Receptors
Papers relating to the observation and 
demonstration of BZ-R began to appear in 1977. Their 
presence in central nervous system (brain and spinal cord) 
can be demonstrated both by radioreceptor assay and 
autoradiography [92,93,94,96,97]. Preparations of
synaptosomes from the cerebral cortex or whole brain minus 
the cerebellum, which has least benzodiazepine receptors 
(BZ-R), are used for benzodiazepine RRA. The BZ-R were 
shown to be highly stereospecific with ( + ) enantiomers 
having a higher affinity for the BZ-R than the (-) form. 
The (+) benzodiazepine enantiomers are 120x more potent 
than (-) at displacing [3H]diazepam from the receptors.
The following criteria has been established in order to 
obtain good affinity binding of benzodiazepines to the 
BZ-R;
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1 Binding must be specific with only one class of 
BZ-R involved.
2 Binding has to be saturable demonstrating a 
definite number of BZ-R sites in the tissue sample.
3 Labelled ligand must bind to the BZ-R with high 
affinity.
NB. Specific binding:- The amount of binding expected
to occur at the receptors and is saturable. 
Non-specific binding (NSB):- Remaining binding 
(background) - absorption to glassware etc which 
cannot be displaced by excess ligand. NSB 
increases linearly with increasing radioligand 
concentration.
In accordance with enzyme kinetics Bmax refers to 
the number of BZ-R in the preparation, whilst KD is the 
dissociation constant of the radioligand from the 
receptor; if Kd  is small then the receptor has a great
affinity for the ligand. Bmax and KD can be
experimentally calculated by binding studies and Scatchard 
plots. Investigations into the effect of temperature on 
RRA with [3H]diazepam gave optimal results after 
incubation at 0°C, where as [ HjFNZ RRA could be 
incubated at room temperature. As both ligands bind to
the same receptors, the optimal incubation temperature 
difference is most likely due to a variation in K^.
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Comparison of in vivo and iji vitro potencies of
benzodiazepines is possible providing all the 
pharmacologically active metabolites involved are 
considered [95] .
The evolution of the BZ-R has been studied as a
means of determing its structure and is present in all
mammals and birds studied, to date, though a species 
difference occurs relating to the proportion of binding 
sites per brain region [98,99,100]. Bony fish possess 
BZ-R with a high affinity for [ 3H] benzodiazepine 
ligands, but not chondrichthyes (sharks) which indicates 
this receptor type was a late evolutionary development.
Sharks do possess some BZ-R with low affinity for
benzodiazepines which must have developed earlier in the
evolutionary timescale.
Work is now being done to determine which specific
protein sequences are necessary for benzodiazepine
specific binding. [3H]FNZ and [ 3H]Rol5-4513 can be
used to irreversibly photolable two proteins in brain
tissue:- P -51kD and p,_ -55kD. They are assumed to 
51 55
be associated with the central receptor as binding of 
[3H]FNZ to each protein is inhibited by diazepam, but 
not by R05-4864 which acts only at peripheral receptor. 
As GABA - a CNS neurotransmitter is probably associated 
with the BZ-R it is possible P 51 and P 55 are different 
subunits of this complex [101]. Comparison of P 51 and
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^55 ^rom different brain regions revealed a high degree 
of homology indicating a definite receptor area which will 
bind to a definite chemical structure such as a 
benzodiazepine [102,103].
The location of two BZ-R subtypes, I - a high 
affinity BZ-R and II - a low affinity BZ-R in human brain, 
was achieved via autoradiography. Quantification was also 
carried out by in vitro labelling of the BZ-R. As the two 
BZ-R subtypes were located in distinct areas of the brain:-
I predominantly in the ventral striatum matrix
II predominantly in the dorsal striatum matrix
it is possible they may be related to various functional 
effects. The proposal is that I is related to 
anti-anxiety effects of BZ and II is related to the 
mediation of muscle relaxation and ataxic effects of 
benzodiazepines [97,103,104].
Benzodiazepines bind to receptors on a variety of 
tissues outside the CNS including; alveolar type II cells, 
heart, lung, erythrocyte membranes and the pineal gland 
[105,106,107,108]. These peripheral binding sites (PBS) 
have been partially purified by gel filtration in an 
attempt to determine their structure [109]. 
Photolabelling with PK 14105, a nitrophenol derivative, 
followed by electrophoresis revealed a low molecular 
weight (18 kD) acidic protein rather than the large and 
complex structure of the central BZ-R. R05-4864, 
Rol5-1788 and FNZ are used to study similarities and 
differences between the two types of receptors [110,111].
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Diazepam and desmethyl diazepam can also be used in this
sense as they have the same affinity for the central BZ-R
but at the peripheral sites diazepam has more affinity for 
the receptors than its metabolite [112].
Surgery affected both central BZ-R and PBS. B
max
had increased by — 30% 3 days after the operation and is
thought to be related to stress and alterations of stress
related hormones such as cortisol, growth hormone and
13-endorphins [113]. There is a correlation with healing
processes as 7 days after surgery when the subcutaneous
tissue and collagen had become re-established, the B
max
was found to have returned to control levels.
As PBS have no known interaction with GABA, other
hormones may be involved in the regulation of these
receptors. An endogenous protein which inhibits Ro5-4864 
binding to PBS has been isolated, purified and named
antralin. It has no effect on the binding of
[3H]Ro15-1788 to central BZ-R. It is thought to 
regulate calcium ion channels via PBR and dihydropyridine
binding sites [114].
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Tile Benzodiazepine/GABA Receptor complex
$f-Aminobutyr ic acid (GABA) is the main inhibitory 
neurotransmitter in the vertebrate central nervous
system. It is formed by the action of glutamate
decarboxylase on glutamate produced by the Krebs cycle.
By increasing permeability of neuronal membranes to 
chloride ions it causes hyperpolarisation and neuronal
inhibition. GABA released from neurones is inactivated by
re-uptake processes and by GABA-transaminase (GABA-T). 
Direct labelling of the receptor with [3H]FNZ allows the 
degradation mechanism to be studied and preliminary
conclusions are that the BZ/GABA-R complex is degraded via 
an energy dependant, non-lysosomal pathway [115].
Benzodiazepines exert their effects by acting on the 
GABA-R and increase GABAergic transmission.
Many projects and studies have since been carried 
out to establish the connection between BZ-R and GABA-R, 
the structure of such receptors, the effects exerted on 
one by the other under normal and stressed conditions and 
the effect of other drugs and chemicals on the proposed 
BZ-GABA complex. A comprehensive review of the 
0 0 q £ £ o phy s i o 1 o gy of BZ—R ligands which incorporates work 
done on BZ-GABA-R complexes is available [116]. Such 
studies provide the most convincing results linking
BZ-GABA systems, as it is possible to study subpopulations 
of benzodiazepines in the various brain regions. Thus
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results from binding studies can be related to their 
physiological functions.
Incubation of ligand/receptor preparations in the 
presence of muscimol increased [^H]diazepam binding,
whereas incubation in the presence of bicuculline 
3
decreased [ H]diazepam binding [117]. Binding to
receptor preparations from 4 day old rats which contain
75% of adult BZ-R but only low levels of GABA-R was not
affected by muscimol or bicuculline. This strengthens the
case for a possible BZ-GABA complex with the receptor
sites located either on the same membrane protein or on
separate but closely associated membrane proteins.
Quantitative autoradiography has been used to study
the reproducibility of benzodiazepine and GABA receptors
and their binding parameters in different areas of cat
brain tissue. Very high levels of BZ/GABA-R were found in
the ventral area of the motor hypothalamus, which is the
region thought to be associated with anxiety. Further
evidence of a BZ/GABA-R complex came from autoradiographic
studies combined with Quantitative radiohistochemistry.
3
The results showed an increase in [ H]benzodiazepine 
binding in all brain regions following the addition of
GABA [118,119].
In vitro study of BZ/GABA receptor development
utilised mouse primary spinal cell cultures as their
binding properties are similar to in vivo spinal cord
cells [120]. During the first 14 days of development KD
j whilst B increased. Addition ofremained the same wniibu max
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GABA to the incubation medium led to a concentration
dependant increase in [ H]FNZ binding, thus BZ-R and
GABA-R are coupled early in neuronal development. GABA
gated chloride channels also develop early as bicuculline
blockage of chloride ion transport was possible from day 3.
Cultured neurons were also used to investigate the
effect of GABA has on the B value of [3H]FNZ
max L J
specific binding [121]. Chronic treatment with 
benzodiazepines caused tolerance to their sedative and 
anticonvulsant effects, but not to their anxiolytic
effects. Prolonged treatment with diazepam decreased the 
ability of GABA to inhibit [3H]DMCM binding. This is
due to a decrease in BZ/GABA coupling rather than a change 
in the benzodiazepine recognition sites. Treatment of 
BZ-R in vitro with GABA agonists and antagonists, muscimol 
and (+)bicuculline, modulate the affinity of 
[3H]diazepam binding increasing the evidence that 
benzodiazepine and GABA receptor sites are linked. 
Conversely, a study of BZ-R ligands on GABA—R revealed
modulation of the receptors by the various ligands.
Muscimol inhibits potassium stimulated release of GABA 
whereas clonazepam potentiates its release. This
modulation of GABA-R by BZ-R may be related to the 
therapeutic actions of benzodiazepines [122,123,124].
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As the BZ/GABA-R is sited in the cell membrane,
membrane lipids can affect the conformation of the 
receptor protein. One such lipid is phosphotidylserine 
which specifically interacts with part of the BZ/GABA-R
complex and facilitates [3H]FNZ binding to the receptors
[125]. It is possible that endogenous phosphotidylserine 
may be involved in the regulation of the BZ/GABA-R 
function.
The above papers describe the emergence of a single 
receptor protein which has a binding site for both 
benzodiazepine and GABA, a ligand-gated chloride channel 
sensitive to muscimol and bicuculline. This complex is 
refered to as the GABA^ receptor. Its function can be 
modulated by a wide range of drugs including
picrotoxin-like anticonvulsants, benzodiazepines and 
barbiturates, which bind directly to the GABA-R complex
[126]. Photoaffinity labelling of crude brain homogenates 
with [3H]FNZ has shown the benzodiazepine binding site 
to be a peptide of Mr = 50-53kD (^-subunit). Labelling
with [3H]muscimol identifies the GABA binding site as a 
peptide of Mr = 56kD (B —subunit). These two peptides 
are thought to form an oligomer incorporating the 
modulatory ligands which form a membrane channel.
Dose/response curves from electrophysical studies predict 
two or more binding sites for the GABA oligomer. The 
B-subunit has 60% of the oc-subunit' s BZ binding capacity 
and as this binding can be prevented by excess cold 
ligand, it may function as a binding site along with the
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c*-subunit. There may be a single oligomeric GABA receptor 
with benzodiazepine and GABA binding on both <=< and 6 
subunits, which are similar. The differences between them 
probably results from variations in binding affinity and 
pharmacological specificity.
Following the emergence of the BZ/GABA-R complex as 
an integrated structure the search is now on to define the 
exact layout of the complex. As the complex shares the 
structural and functional properties with the nicotinic 
and glycine receptor-gated ion channels it is possible 
they evolved from a common gene pool. It has also enabled 
many of the techniques and approaches used to study the 
nicotinic acetylcholine receptor to be used to purify the 
BZ/GABA-R in sufficient quantities, thus enabling detailed 
studies of its molecular and structural properties 
[127,128].
The presence of an c<-subunit of 50-53kD and a
B-subunit of 55-58kD have been confirmed by SDS-PAGE.
Incubation of the c*-subunit (BZ-R site) with glycosidases
indicates the presence of glycosides in varying degrees
depending on the brain region, which could relate to the
BZ-R heterogenicity [128]. Using monoclonal antibodies to
the or B subunit it is possible to show the
GABA -R complex has both. The subunit stoichiometry has 
A
been found to be a tetramer - Mr~230kD.
Recombinant DNA cloning of <=< and B demonstrated a 35% 
homology in their amino acid sequences. Antibodies raised 
against a nonapeptide sequence of the BZ/GABA c*_subunit
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demonstrates the existence of heterologous regions of 
ex-subunit in the cerebral cortex [129].
As benzodiazepines have sedative, muscle relaxant 
and anticonvulsant effects, projects to study 
modifications of these effects are often carried out using 
rat and mouse artificially induced seizure models 
[130, 131, 132, 133]. An example of this is the 
interper itoneal (ip) administration of DMCM to mice to 
study its pharmacological effects. A series of 
benzodiazepines were given both ip and orally prior to 
DMCM dosing at concentrations which inhibited the seizures 
[130]. Theory indicates that the BZ/GABA-R complex has 
two conformations which are in equilibrium and 
benzodiazepines have a high affinity for the open chloride 
channel form. Any benzodiazepines binding to the receptor 
moves the equilibrium, increasing the number of open 
channels enabling chloride ions to enter the cell. DMCM 
is thought to have a high affinity for the closed channel 
conformation 'locking' the receptor in this state and 
decreasing benzodiazepine mediated GABA neurotransmission.
In additition to the study of in vivo and in vitro 
effects of drugs on the BZ/GABA-R complex, other factors 
such as age, ethanol and mental state of subject can also 
modulate the BZ/GABA-R complex.
Effects of ageing on ethanol and diazepam 
modulation of GABA binding sites have been demonstrated 
[134]. When taken together ethanol and diazepam act 
synergistically to depress the CNS. diazepam acts on the
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BZ-R to increase chloride ion transport, whereas ethanol 
increases chloride ion transport in a non-specific way by 
increasing the fluidity of the cell membranes. Age has no 
effect on B but may affect K .  In the absence of
III a X  ]j
ethanol, diazepam influences the GABA^ binding site in 
all age groups. When ethanol was present the influence of 
diazepam on the GABA^ binding site decreased with age.
This was due to age related changes in the phospholipid 
content and composition of the membranes. Chronic ethanol 
treatment is also thought to uncouple the BZ/GABA-R 
complexes in the brain [45].
GABA is also thought to be involved in depressive 
illnesses as low levels of GABA have been described in 
such patients prior to treatment [135].
CHAPTER TWO
T_o Establish the Radioreceptor Assay Protocol 
2:1 Introduction
Before the radioreceptor assay could be used as a 
working method to analyse the greyhound urine samples, 
various parameters have to be experimentally defined. 
This involved a series of mini-experiments to look at the 
individual aspects of the RRA. Due to the nature of the 
assay, the first experiments were related to the 
preparation and evaluation of benzodiazepine receptors. 
Preparation involved separating the synaptosomal fraction, 
containing the receptors, from homogenised brain tissue by 
centrifugation. The resulting pellet was assayed to 
determine its protein concentration, which was used as a 
guide to receptor concentration. As the receptors are 
prepared in batches from rats of similar weights and ages, 
determination of the protein concentration of one vial can 
be used to estimate the protein concentration of the
remaining vials.
Once the protein concentration of a particular vial
has been established, a more specific estimation of the
receptor number (B ) can be made. This is done by 
* max
carrying out a binding assay — a variation of the RRA 
reguiring a series of radioligand standards rather than a
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series of benzodiazepine standards. The Packard 
Combicept™ program translates the data into two graphs, 
calulating Bmax from each. The dissociation constant 
(K^) is also calculated in this way.
A group of three experiments relating to practical 
aspects of the RRA were carried out. The first was to 
establish the length of time the receptors could be stored 
at -20 C, both as the whole brain tissue and as the 
prepared synaptosomal fraction. Once an assay has been 
set up, it has to incubate for a set period to allow the 
receptors and the ligand/radioligand to reach 
equilibrium. Determination of the optimum length of this 
period formed the basis of the second experiment. The 
reversal of this equilibrium by the addition of excess 
unlabelled ligand was also noted.
At the end of incubation the bound and free
radioligand have to be separated. This can be achieved by
either filtration or centrifugation [136], as the BZ-R is
in the particulate form. Soluble receptors, such as those
for hormones, require an alternative method such as
precipitation or gel filtration chromatography [1].
Filtration is the most widely used separation method as it
is quick and efficient. The total separation time -
filtration and washing of the filters, is about 10-20
—  8
seconds/sample which requires to be 10 nM or
less. As values for benzodiazepines are in this range, 
filtration is applicable to RRA of urine samples for
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benzodiazepines. The main disadvantage of filtration is 
the non-specific binding of the radioligand to the filters 
and filtration system. This can be minimised by washing 
the filters. The number of washes required to reduce NSB 
to a minimum, whilst retaining a total separation of 10 to 
20 seconds formed the basis of the third experiment.
When the NSB cannot be reduced to manageable levels 
or when is rapid, centrifugation is the alternative,
though it is less efficient than filtration. Washing and 
re-centrifugation of the pellet increases separation time, 
thus has to be small. Eliminating the wash period
increases the NSB due to free radioligand trapped in the 
pellet.
Several studies were carried out to assess the 
potency of various benzodiazepines and non-benzodiazepines
3
to displace [ H]FNZ from the BZ-R. The potency of a
compound in such circumstances is usually refered to as
its K. value. The smaller the K. value, the lower the 
l i
concentration of drug required to produce a biological or 
clinical effect. In this way values are often used
to predict the recommended daily doses of a drug.
Experimentally it is the value - the amount of drug
to displace 50% of radiolabel, which is measured and used 
to calculate the value. *^50 an<  ^ ^i v a lues were
obtained for several different benzodiazepines and a 
selection of their metabolites.
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A variety of non-benzodiazopines, representing most 
pharmaceutical classes, were assayed with [3H]FNZ as the 
radioligand. This was to establish their lack of cross 
reaction with the BZ-RRA and to demonstrate the low 
affinity of non-benzodiazepines for the BZ-R.
When all these experiments had been carried out, 
the collective results were assessed and a protocol for 
radioreceptor assay of benzodiazepines drawn up. This 
formed the basis for the analysis of the greyhound urine 
samples for selected benzodiazepines.
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2:2 Equipment and Materials
Centrifuge
Scintillation
Counter
Data processing
Radioligand
Filters
Scintillant
Pico 'Hang- 
I n 1 vials
Beckman JA 2-21 with JA 20 rotor.
Packard 2200 CA Tri-Carb®
Liquid Scintillation Analyser.
Binding Assay - Packard Combicept™ 
program for IBM®-PCAT.
RIA - Packard SecuriaT program for 
IBM®-PCAT.
3
N-Methyl [ HJFlunitrazepam 
Amersham International.
Whatman® GF/B glass microfibre 
filters.
Ecoscint A®, National Diagnostics. 
Packard®.
LP3 tubes Luckham Ltd.f
Disposable Laboratory Plastics.
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Drugs
Alprazolam 
Bromazepam 
Clonazepam 
Diazepam & 
metabolites 
Flunitrazepam 
& metabolites 
Lorazepam 
Nitrazepam 
Oxazepam 
Triazolam & 
metabolites
Amphetamine
Aspirin
Amytriptyline
Amylobarbitone
Caffeine
Chloroquin
Chlorpromazine
Morphine
Paracetamol
Propranolol
Quinine
Upjohn Ltd.
Roche Products Ltd.
Roche Products Ltd.
Roche Products Ltd.
Roche Products Ltd.
Wyeth Laboratories.
Roche Products Ltd.
M.A. Steinhard Ltd.
Upjohn Ltd.
Sigma® Chemical Company Ltd. 
Sigma® Chemical Company Ltd. 
Berk Pharmaceuticals Ltd.
Eli Lilly & Company.
Sigma® Chemical Company Ltd. 
I.e.I. Pharmaceuticals (UK). 
May and Baker Ltd.
Sigma® Chemical Company Ltd. 
Winthrop Laboratories.
Berk Pharmaceuticals Ltd. 
Sigma® Chemical Company Ltd.
All other chemicals were of analytical grade.
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2 : 3 Experimental Methodology
Note: All [ HJFNZ dilutions were made with 25mM sodilum
phosphate assay buffer, pH 7.4. The receptor preparation 
was diluted where necessary with 25mM sodium phosphate
assay buffer, pH 7.4. Benzodiazepine standards were made 
up either in 25mM sodium phosphate assay buffer, pH 7.4, 
or drug free greyhound urine centrifuged to remove any 
particulate matter. Throughout all the experiments "assay 
buffer" refers to 25mM sodium phosphate buffer, pH 7.4.
2:3:1 Preparation of Benzodiazepine Receptors
Male Sprague-Dawley rats were stunned and 
decapitated to allow easy removal of the brain tissue. 
The whole brain minus the cerebellum was removed, 
immediately frozen and stored at -20°C until required. 
The mitochondrial fraction containing the synaptosomes in 
which the BZ-R are located was prepared by hand 
homogenisation of lg of brain tissue in 5 volumes of ice 
cold 0.32M sucrose solution. The homogenate was
centrifuged for 10 minutes, spin speed 3500g, at 4 C and 
the pellet discarded. The remaining supernatant was
centrifuged for 20 minutes, spin speed 15000g, at 4 C,
this time the supernatent was discarded and the weight of 
the pellet noted. Resuspension of the pellet in 5 ml of 
assay buffer enabled it to be transferred to a suitable
vial and stored at -20°C until required.
2:3:2 Protein Assay
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The protein assay, a colourimetric method [137], is 
carried out using bovine serum albumin to prepare the 
standard curve. The coloured complex which is measured in 
a spectrophotometer, and directly relates to the protein 
concentration, is due to tyrosine and tryptophan residues 
in the protein complexing with the alkaline copper-phenol 
reagent.
Reagents
1 Sodium carbonate, 2% w /v in 0.1M NaOH.
2 Copper sulphate (hydrated), 1% w /v in water.
3 Sodium potassium tartrate, 2% w /v in water.
4 Bovine serum albumin 100 ug/ml in 0.5M NaOH.
Prepare fresh copper reagent by mixing reagents 1:2:3 in 
the proportions 100:1:1.
The brain preparation is assayed at 2 dilution levels, 
1/10 and 1/50, in order to obtain a more accurate 
determination of its concentration. 0.5M NaOH was the 
diluent in both cases.
Method
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Reagent Volume added (ml)
Sample/Std 0.0 0.2 0.4 0.6 0 . 8 1.0
0.5M NaOH 1.0 0.8 0.6 0.4 0.2 0.0
Cu reagent 5.0 5.0 5.0 5.0 5.0 5 . 0
Vortex. stand for 10 minutes at 2 5°C
IN Folin reagent 0.5 0.5 0.5 0.5 0 . 5 0.5
Vortex, stand for 30 minutes at 25°C.
Read absorbance at 540nm using one O.Omg.ml 
sample, as blank.
Plot absorbance against bovine serum albumin (ug) 
assay to generate a standard curve from which the pro 
concentration of the samples can be read directly, 
standard curve is linear over the range of standards us
2:3:3 Binding Study
This was carried out to determine the dissocia
constant, K , and the number of receptors available 
D
binding in a preparation of brain tissue, Bm a x ’ 
data generated can be plotted in a variety of ways which 
are discussed in section 2:4.
per
tein
The
ed.
tion
for
The
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Standards, made up in drug free greyhound urine: 
Diazepam: 0, 10, 25, 50, 100, 200ng/ml.
Triazolam: o, 1 , 5, 10, 15, 20, 25, 35, 50ng/ml.
FNZ: 25, 50, 100, 200ng/ml.
3
[ H]FNZ, made up in assay buffer:
10, 25, 50, 100, 200, 400, 500, 600,
800, looonci,.
Method - Total Binding
10 pairs of LP3 tubes were set up to enable each
3
[ H]FNZ concentration to be assayed iji duplo. Each tube
contained an incubation mix consisting of 400ul receptor
3preparation, Img/ml, lOOul of the appropriate [ HJFNZ 
concentration and 50ul assay buffer. After each tube was 
vortexed, to ensure thorough mixing, they were incubated
for 30 minutes at 25°C. The bound and free fractions 
were separated by filtration under vacuum and the filters 
washed with 5 x 1ml of assay buffer. The filters were 
placed in to Pico vials, 4ml of scintillant was added and
the vials shaken vigerously. Counting was for 1 minute
and gave the DPM of the bound radioligand.
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Method - Non-Specific Binding
10 pairs of LP3 tubes
3[ H]FNZ concentration to be 
contained an incubation mix 
preparation, lmg/mlf 
concentration and 50ul 
was vortexed, to 
incubated for 
fractions were 
the filters washed with 
filters were placed in to 
was added and the vials 
for 1 minute and gave the
5
were set up to enable each 
in duplo. Each tube 
of 400u1 receptor 
[3H]FNZ 
each tube 
they were 
and free 
vacuum and 
buffer. The 
scintillant 
Counting was 
radioligand.
assayed 
consisting 
lOOul of the appropriate 
triazolam lug/ml. After 
ensure thorough mixing,
30 minutes at 25°C. The bound 
separated by filtration under 
x 1ml of assay 
Pico vials, 4ml of 
shaken vigerously.
DPM of the bound
The DPM of total added label was determined by 
addition of lOOul of each radioligand concentration 
directly to 4ml of scintillant which was counted for 1 
minute.
2:3:4 Rat Brains and Receptors - Storage Study
The length of time rat brains and receptors can be
stored at -20°C was determined by preparing sets of
receptors and assaying them over a period of six weeks. 
The triazolam standards were made up in blank greyhound 
urine. 10 pairs of LP3 tubes were set up enabling
duplicates of each standard to be assayed.
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Std. Curve
Triazolam 
(nq/ml) volume (ul)
0
1
5
10
15
20
25
35
50
NSB
1000
50
50
50
50
50
50
50
50
50
50
[ H]FNZ R preparation 
volume (ul)
100 400
100 400
100 400
100 400
100 400
100 400
100 400
100 400
100 400
100 400
Each tube was vortexed, to ensure thorough mixing, 
and incubated for 30 minutes at 25°C. The bound and 
free fractions were separated by filtration under vacuum 
and the filters washed with 5 x 1ml of assay buffer. The 
filters were placed in to Pico vials, 4ml of scintillant 
was added and the vials shaken vigerously. Counting was 
for 1 minute and gave the DPM of the bound radioligand.
Non-specific binding (NSB) includes any free radioligand 
not washed away, that bound to the non-receptor fraction 
of the brain preparation, and that bound to the separation
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materials - filters, assay tubes etc. Following assay of
the standards, C /C is calculated for each standard
o x
and plotted against the triazolam concentration to create 
a standard curve. An example of a set of results for such 
a standard curve is shown in table 2:1, with the 
appropriate graph shown in figure 2:1.
CQ = CPM for the 0 standard (50ul AB) minus CPM for the 
NSB standard.
C = CPM for 50u1 standard/sample minus CPM for the 
x
NSB standard.
Table 2:1 Set of Experimental Data to Illustrate a 
Radioreceptor Assay Standard Curve.
Triazolam
(ng/ml)
X DPM C
X
C /C 
0 X
0 824 . 4 786 . 6
1 693 . 3 655 . 5 1.2
5 599 . 6 561.8 1.4
10 198 . 3 160. 5 4 . 9
15 122 . 3 84 . 5 9 . 3
20 136 . 1 98 . 3 8.0
25 100.7 62 . 9 12.5
35 77 . 1 39 . 3 20 . 0
50 70.0 32 . 2 24 . 4
NSB 37 . 8
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Figure 2:1 An example of a radioreceptor assay 
standard curve for triazolam.
24
20
16
12
8
4
0
0 10 20 30 40 50
Triazolam concentration (ng/ml)
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2:3:5 Specific Binding v. Time
Firstly, to determine the stable period of the
receptor/ligand equilibrium. 42 LP3 tubes were set up in
pairs, enabling duplicates to be filtered every 15 minutes
from t to t„^ . Each tube contained an incubation mix 
0 300
consisting of 400ul receptor preparation, lmg/ml, lOOul of 
[3H]FNZ ,50nCi, and 50ul assay buffer. After each tube 
was vortexed, to ensure thorough mixing, the bound and 
free fractions were separated by filtration under vacuum 
at 15 minute intervals. The filters were washed with 5 x 
lml of assay buffer and placed in to Pico vials, 4ml of 
scintillant was added and the vials shaken vigerously. 
Counting was for 1 minute and gave the DPM of the bound 
radioligand. DPM were plotted against time.
Secondly, to obtain the association curve where the
3 . . .
BZ-receptors and [ HJFNZ reach equilibrium and to
demonstrate its reversal by the addition of excess 
triazolam.
50 LP3 tubes were set up in pairs, enabling
duplicates to be filtered every 5 minutes from t to
0
t 120 *
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Incubation Mix - Association Curve
Each of the first 13 pairs of tubes contained an 
incubation mix made of 400ul receptor preparation, lmg/ml, 
lOOul of [3H]FNZ, 50nCi, and 50ul assay buffer. After 
each tube was vortexed, to ensure thorough mixing, they
were incubated for 30 minutes at 25°C. The bound and 
free fractions were separated by filtration under vacuum 
at 5 minute intervals. The filters were washed with 5 x 
lml of assay buffer and placed in to Pico vials, 4ml of 
scintillant was added and the vials shaken vigerously. 
Counting was for 1 minute and gave the DPM of the bound 
radioligand. DPM were plotted against time.
Incubation Mix - Dissociation Curve
The remaining 12 pairs of LP3 tubes had 400ul of
3lmg/ml receptor preparation and lOOul of 50nCi [ H]FNZ 
added to them and were vortexed. After a 60 minute
incubation period 50 ul of lug/ml triazolam was added to
the tubes followed by thorough mixing. Filtration was 
begun immediatley at 5 minute intervals. The filters were 
washed with 5 x 1ml of assay buffer and placed in to Pico 
vials, 4ml of scintillant was added and the vials shaken 
vigerously. Counting was for 1 minute and gave the DPM of 
the bound radioligand. DPM were plotted against time.
- 40 -
2:3:6 Separation of Bound and Free Radioligand
RRA, as described below, were carried out with 
several sets of triazolam standards, each made up in drug 
free greyhound urine. At the filtration stage each set of 
filters were washed with different volumes of assay 
buffer. Following several repetitions, the data was 
assessed to determine the least number of washes required 
to minimise the NSB. Four different volumes of assay 
buffer were used: 1ml, 3ml, 5ml & 10ml.
As before 10 pairs of LP3 tubes were set up, one 
for each of the triazolam concentrations in duplicate.
Std. Curve
3Triazolam [ H]FNZ R preparation
(nq/ml) volume (ul) volume (ul)
0 50 100 400
1 50 100 400
5 50 100 400
10 50 100 400
15 50 100 400
20 50 100 400
25 50 100 400
35 50 100 400
50 50 100 400
NSB
1000 50 100 400
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Each tube was vortexed, 
and incubated for 30 minutes 
free fractions were separated 
and the filters washed with 5 x 
filters were placed in to Pico 
was added and the vials shaken 
for 1 minute and gave the DPM of
2:3:7 Inhibition of Radioligand
to ensure thorough mixing,
at 2 5°C. The bound and 
by filtration under vacuum 
1ml of assay buffer. The 
vials, 4ml of scintillant 
vigerously. Counting was 
the bound radioligand.
Binding to Receptors
RRA, as described below, were carried out with sets 
of benzodiazepine standards covering a range of 0 to 
200ng/ml, each made up in drug free greyhound urine. Nine 
different benzodiazepine and six metabolites were used as 
below:
Benzodiazepine Metabolite
Alprazolam
Bromazepam
Clonazepam
Diazepam 3-hydroxy diazepam
Desmethyl diazepam 
Flunitrazepam Desmethyl flunitrazepam
7-amino flunitrazepam
Lorazepam
Nitrazepam
Oxazepam
Triazolam l'-hydroxy triazolam
4-hydroxy triazolam
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Standard ranges:
0, 1. 5, 10, 25, 50, 75. 100, 200, lOOOng/ml
for alprazolam, bromazepam, clobazam, clonazepam, 
diazepam, N-desmethyl diazepam, 3-hydroxy diazepam, 
flunitrazepam, desmethyl flunitrazepan, 7-amino
flunitrazepam, lorazepam, nitrazepam, oxazepam, triazolam 
& l ’-hydroxy triazolam.
and 0.1, 0.5, 1, 2, 4, 5, 6, 8, 10ug/ml 
for 4-hydroxy triazolam.
As before 10 pairs of LP3 tubes were set up. one 
for each of the benzodiazepine concentrations in
duplicate.
Std. Curve
3Benzodiazepine [ H]FNZ R prepar
(nq/ml) volume (ul) volume (ul)
0 50 100 400
1 50 100 400
5 50 100 400
10 50 100 400
15 50 100 400
20 50 100 400
25 50 100 400
35 50 100 400
50 50 100 400
NSB
1000 50 100 400
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Each tube was vortexed, to ensure thorough mixing, 
and incubated for 30 minutes at 25°C. The bound and 
free fractions were separated by filtration under vacuum 
and the filters washed with 5 x lml of assay buffer. The 
filters were placed in to Pico vials, 4ml of scintillant 
was added and the vials shaken vigerously. Counting was 
for 1 minute and gave the DPM of the bound radioligand.
2:3:8 BZ-RRA and Non-Benzodiazepines
50ug/ml stock solutions of each of the non-BZ were 
made up in and diluted with assay buffer to give a working 
standard range as follows:
0, 10, 20, 30, 40, 50ug/ml.
To confirm the presence of the drugs, each standard was 
subjected to a U.V. scan against blank assay buffer. 
Where necessary the pH of the buffer was changed. Table 
2:2 lists the compounds used together with their U.V. 
absorbance maxima at pH 7.4, (pH changes indicated where 
made).
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Table 2:2 List of Non-benzodiazepines and Their U.V. 
Absorbance Maxima.
COMPOUND U.V. ABSORBANCE MAXIMA nm
Amphetamine 258 265
Aspirin 230 280 (pH 2)
Amytriptyline 242
Amylobarbitone 256 (pH 13)
Caffeine 275
Chloroquin 261 334 347
Chlorpromazine 264
Morphine 287
Paracetamol 245
Propanol 288 306 319
Quinine 253 320 (PH 2)
6 pairs of LP3 tubes were set up, one for each
the non-BZ concentrations in duplicate and 10 pairs of LP3 
tubes were set up, one for each of the diazepam standards 
in duplicate.
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std. curve
Diazepam 
(na/ml) volume (ul)
0 50
10 50
25 50
50 50
100 50
200 50
NSB
1000 50
[ H]FNZ R preparation 
volume (ul)
100 400
100 400
100 400
100 400
100 400
100 400
100 400
Each tube was vortexed, to ensure thorough mixing, 
and incubated for 30 minutes at 25°C. The bound and 
free fractions were separated by filtration under vacuum 
and the filters washed with 5 x 1ml of assay buffer. The 
filters were placed in to Pico vials, 4ml of scintillant 
was added and the vials shaken vigerously. Counting was 
for 1 minute and gave the DPM of the bound radioligand.
3The non-BZ standards were deliberately made 10 x 
that of the diazepam standards to enable any cross 
reaction with the BZ-R to be seen.
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2:4 Results and Discussion
The previous pages have described the experiments 
carried out to assess the various aspects of the R R A . 
Preparation of the receptors was a straight forward method 
whereby the homogenised rat brain tissue was centrifuged 
twice. This produced a pellet containing sufficient 
viable receptors per mg of protein to set up a RRA with 
appropriate volumes. Table 2:3 contains data to construct 
a protein calibration curve which is shown in figure 2:2.
Table 2:3 Experimental Data from a Protein Assay.
Standard Curve 
uq protein/ml mean absorbance
0.0 0.07
20.0 0.1
40.0 0. 12
60.0 0. 14
80.0 0 . 16
100.0 0. 19
Table 2:4 lists the data from the two dilutions of 
the receptor preparation used. When all the dilutions 
have been taken into account it is possible to calculate 
the protein concentration of the pellet.
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Figure 2:2 An example of a protein calibration curve.
Ave rage 
absorbance 
(nM)
0.20 r
0.16
0.12
0.08
0.04
0.00
4020 60 80 100
Protein concentration (ng/ml)
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Table 2:4 U.V. Absorbtion Data from the Two Dilutions 
of the Receptor Preparation Pellet.
Samples
1/10
Dilution Average
absorbance
ug pt/ml Equilibration of 
ug pt/ml to 1ml dilution
0.2 0.09 15.0 75.0
0.4 0.11 32.0 80.0
0.6 0 .15 66.0 110.0
0 . 8 0. 17 83.0 103 . 0
1.0 0 . 20 118 .0 118 .0
Average 97.0
1/50
Dilution Average
absorbance
ug pt/ml Equilibration of 
ug pt/ml to 1ml dilution
0.2 0.07 0.0 0.0
0.4 0.07 0.0 0.0
0.6 0.08 7.0 11. 6
0.8 0 . 09 15 .0 IB .7
1.0 0.09 15.0 15.0
Average 15.1
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Estimation of the protein concentration of each
pellet by photospectrometry revealed the average protein 
concentration of lg of brain tissue to be between 1 and
2mgf after resuspension in 5ml of assay buffer. A
selection of prepared pellets, their weights and protein 
concentrations are shown in table 2:5. Also shown are the 
volumes of assay buffer required to give a final protein 
concentration of lmg/ml.
Table 2:5 Results from the Assay of Prepared Pellets to 
show the Concentration of Protein in each
Preparation.
Weight of Protein Cone. Final protein
pellet (mg) mg/ml Vol made up to conc. (mg/ml)
__________ lmg/ml with_AB________________________
1.8 0.55 1.0
1.4 0.71 1.0
2.1 0.47 1.0
1.8 0.55 1.0
1.8 0.55 1.0
1.2 0.83 1.0
1.5 0.66 1.0
1.5 0.66 1.0
44 .4 
32 .7
51.7 
45.3 
42 .1
30.7 
36.2 
36.1
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Accordingly a protein concentration of lmg/ml was 
used as a working concentration for the benzodiazepine 
radiorecptor assay (BZ-RRA).
As the binding study and the experiments to assess
the storage time of prepared receptors and whole rat
brains, were carried out prior to those assessing the
incubation period and washing of the filters, literature
values were used where necessary. The incubation period
was taken as between 30 and 60 minutes and the filters
washed with 10ml of assay buffer [9,10,11,12,13,14]. When
the appropriate experimental data had been established
both studies were repeated with an incubation period of 30
minutes and with the filters being washed with 5 x 1ml
assay buffer. Once the protein concentration for each
pellet has been estimated it is possible to make a more
accurate determination of the receptor number in each
pellet. The binding assay forms the experimental part
with the data obtained being transformed by a variety of
calculations and graphs to determine K and B
D max
Subtraction of the NSB DPM results from the total bound
DPM results produces the DPM for the specifically bound
3 . .[ H]FNZ. A set of experimental results to highlight
this part are shown in table 2:6.
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Table 2:6 Experimental Results from a Binding Assay for 
Total, NSB and Specific Binding of [3H]FNZ 
to the Benzodiazepine Receptors.
r3H]FNZ
Average 
(nCi) Total Bound
DPM
NSB Specifically Bound
10 99.75 104 . 5 -4.75
25 208.05 81.7 126.35
50 304.95 89 . 3 215.65
100 712.5 98 . 8 613 .7
200 1411.7 168.15 1243 . 5
400 2489 . 0 281. 9 2207.1>
600 2874 .7 395 . 4 2479.3
800 3459.9 411. 3 3048 . 6
1000 3887 . 4 507.3 3380.1
Figure 2:3 is a plot of the data from figure 2:6
whereby total (A), specific (B) and non-specific binding
(C) of [3H]FNZ are plotted against increasing [3H]FNZ
concentration (nCi). The specific binding of the
radioligand is saturable, whereas the NSB increases
linearly with increasing radioligand concentration, both
necessary requirements for a workable RRA. These results,
together with the DPM of the total radioligand added, are
transformed by the Combicept™ program [138], to
determine K and B via the Scatchard plot,
D max
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Figure
Ave rage 
DPM
2:3 Total, non-specific and specific binding 
of tritiated flunitrazepam.
4000
2000
0
400200 6000 800 1000
Tritiated flunitrazepam concentration (nCi)
A - Total binding.
B - Specific binding.
C - Non-specific binding.
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[1,94,113,139,140,141,142,143]. This graphical method
remains popular despite publications relating to the
errors in the correction and interpretation of such plots,
[144,145,146,147]. Often, as with the Combicept™
program, the data is used to draw a Scatchard plot and a
saturation curve with a value obtainable from each by-
extrapolation of the data. Theoretically these values
will be the same from both plots, but often slight
differences occur due to the different way the graphs, and
therefore the values, are calculated. The same applies to
the B value which is also obtainable from both
max
graphs. Below is a comparison of Scatchard and saturation 
plots which emphasises the errors associated with plotting 
a Scatchard curve:
1 The points at the top of the Scatchard plot relate
to the low concentrations of radioligand thus are the 
source of greatest error, but they are often used to 
determine where the line is drawn.
The same points on a saturation plot are near the
origin and do not have as much bearing on the shape of the
graph.
2 As the data points forming the Scatchard plot are
often clustered in the top half of the graph,
extrapolation to obtain B can result in a large error
max
as there are fewer or no points near the intersection with 
the X axis.
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With the saturation plot the data points are spaced 
more evenly with those more likely to be accurate near the 
top of the graph, the part used to determine K^.
Figures 2:4 and 2:5 are theoretical plots which 
demonstrate the above points [148].
The Combicept program™ incorporates both an 
orthogonal weighting scheme and the Rosenthal correction 
for NSB subtraction [149]. The former statistically 
eliminates some of the errors encounted during data 
transformation to the scatchard form; however the 
saturation curve is still recommended as the best way of 
analysing data from a binding study.
Papers are also available which demonstrate varied 
ways of analysing data from receptor assays, the use of 
computer modelling to obtain the optimum conditions for 
RRA and also programs to calculate the errors involved, 
[150, 151, 152,153] .
Experimental data obtained from a binding study, 
protein concentration - 0.12mg/ml, is shown in table 2:7; 
and plotted both as a Scatchard plot and a saturation 
curve which are shown by figures 2:6 and 2:7.
Figure 2 s4 Theoretical saturation plot to demonstrate 
the relatively even spacing of the points.
Total tritiated flunitrazepam added (nCi)
Sb - Specifically bound tritiated flunitrazepam.
Figure 2:5 Theoretical Scatchard plot to demonstrate
how the points are clustered near the top 
part of the graph.
Sb/F
Specifically bound tritiated flunitrazepam (pM/mg pt)
Sb/F - Specifically bound tritiated flunitrazepam over 
free tritiated flunitrazepam (pM/mg pt/nM).
* - Due to a fault in the commercial program this second 
point was discounted when the saturation and Scatchard 
plots were drawn.
\
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Table 2:7 Experimental Binding Assay Data.
[3H]FNZ Sb [3H]FNZ Sb/F
(nCi)___________ pM/mg protein___________ pM/mg protein/nM
0.0306 0.0015 0.0520
0.0071 0.0034 0. 9347 —
0.1401 0.0044 0.0323
0. 3360 0.0101 0.0313
0.6669 0.0201 0.0312
1.1514 0.0258 . 0.0230
1.5888 0.0332 0.0215
2 .0651 0.0372 0.0184
2.7668 0.0433 0.0160
3.1141 0.0486 0.0159
The K~ and results obtained from this data areD max
as follows:
Scatchard plot Saturation Curve
k d
2.3 6nM 2.3 2nM
Bmax 962fmol/mg pt 938fmol/mg pt
There is significant correlation between the points 
forming the Scatchard plot, as the regression coefficient 
= 0.961.
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Figure 2:6 Scatchard plot from a set of experimental data,
protein concentration 0.12mg/ml.
0.33
Gradient = 1/K
0.22
0.11
max
0. 550.18 0. 37 0.740 0.92
Specifically bound tritiated flunitrazepam (pM/mg pt)
Sb/F - Specifically bound tritiated flunitrazepam over 
free tritiated flunitrazepam (pM/mg pt/nM) .
intersection with the X axis.max *
KD - The reciprocal of the gradient of the line.
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Figure 2:7 Saturation plot from a set of experimental data,
protein concentration 0.12mg/ml.
0.053
0.043 max
0.032
0.021
0.011
3.4262.055 2.741.370.6850
Total tritiated flunitrazepam added (nCi)
Sb - Specifically bound tritiated flunitrazepam. 
Bmax ” The horizontal assymptote to the curve.
Kd - This is proportional to the slope of the curve 
at the origin.
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Binding studies were carried out with varying 
concentrations of protein, the results of which are shown 
in table 2:8. Protein concentrations below lmg/ml gave 
results consistent with literature values, better 
correlation between data points and greater consistency 
between binding studies. Results from assays where the 
protein concentration was above lmg/ml were more 
variable. This was thought to be because of the increased 
number of receptors enabling binding of both labelled and 
unlabelled ligand in a less competitive manner. Therefore 
the extrapolation of the results to saturation will be 
less accurate.
Table 2:8 A Compilation of Several Sets of Results from 
Scatchard and Saturation Plots with Varying 
Protein Concentrations.
Protein Saturation Scatchard Correlation
ug pt/ml k b  k b coefficient
D max D max
4 . 5 9 . 73 713 14 . 40 1011 0 . 52
3 . 5 2 . 10 17 3 . 20 23 0 . 656
2.3 9.73 1003 14 . 60 2000 0 . 524
1.7 1.81 59 1. 58 55 0.9074
0.12 2 .32 938 2 .36 962 0 .961
0.06 1.96 1710 1.51 1516 0.9079
0 . 01 1. 81 10000 1.58 9400 0.9074
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Experiments carried out to determine the length of 
time the receptors could be stored resulted in a series of 
graphs, of which figure 2:1 is an example. As the curve 
is linear over the chosen standard range it is possible to 
calculate the- gradients of each line for comparison. 
Results for assays carried out over a 6 week period are 
shown in table 2:9 and are the averages of such data 
gained from 3 experiments for every 7 day interval, 
following receptor preparation.
Table 2:9 Data Relating to Radioreceptor Assays using 
Receptor Preparations up to Six Weeks After 
Preparation.
C /C 
o x
Triazolam Week no.
(ng/ml) 1 2 3 4 5 6
1.0 1.2 1.1 1.3 1.1 1.2 1.0
5.0 1.8 1.4 1.7 1.6 1. 6 1.1
10.0 3 . 4 1.0 2 . 9 2 . 5 3 . 1 1.8
15.0 6 . 4 4.4 4.7 4.0 4.7 2 . 8
20.0 9 . 4 7 . 4 7 . 4 6 . 8 4 . 8 1.8
25.0 11.0 10. 4 12 . 9 9.5 6 . 5 2 . 2
35.0 13 . 4 21.4 16 . 5 15 . 3 12 . 8 3 . 0
50 . 0 21. 4 22 . 7 21. 5 26 . 1 17 . 0 2 . 7
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Combinations of each weeks results are shown in 
table 2:10 as average values.
Table 2:10 The Combined Results of Weeks 1 to 6 Listed 
as Average Values.
Triazolam 
(ng/ml) 1 + 2
Average
Weeks
1-3
C /C values
o X
combined 
1-4 1-5 1-6
1.0 1.15 1.2 1.2 1. 18 1.0
5.0 1. 6 1.63 1. 6 1. 62 1.53
10.0 2 . 2 1.63 2 . 4 2 . 58 2 .45
15 .0 5 . 4 5.16 4 . 8 4 . 84 4 . 5
20.0 8 . 4 8 . 1 7.7 7 . 16 6 .26
25.0 10.7 11.4 10.9 10. 1 8.75
35.0 17 . 4 17 . 1 16 . 6 15 . 9 13 . 7
50.0 22 .1 21.8 22 . 9 21.74 18 . 6
From these 'average value' results it is difficult
to determine any significant changes with time. Therefore
the paired t-test [154] was used to statistically compare
results from one week with those of previous weeks. This
method is preferred to a comparisom of means as the
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differences in the results are comparatively large 
especially when week 6 is considered. By taking the null 
hypothesis approach, the means of the differences between 
pairs of results can be tested, with the following 
formula, to determine whether they significantly differ 
from zero.
t = (x-u) 
n/s
x = mean of samples
u = mean of population
s = standard deviation of samples, with s,(n-1)
n = sample size
t = the quantity used in significance testing and
has (n-1) degrees of freedom when p = 0.05
Therefore t = xd
y^7id
x = mean of differences
s, = standard deviation of differences 
d
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The various comparisons of the results from weeks l 
to 6 are listed below and the corresponding values of t 
are shown in table 2:11.
1 Week 1 V. week 2 .
2 Weeks 1 & 2 V. week 3 .
3 Weeks 1 - 3 V. week 4 .
4 Weeks 1 - 4 V. week 5 .
5 Weeks 1 - 4 v. week 6 .
Table 2:11 A Statistical Comparison of the 
Results of the Storage Study.
Week
number
Values of t
1 v 2 0.35
1+2 v 3 0.00
1-3 v 4 0. 84
1-4 v 5 9 .16*
1-4 v 6 49 36*
Values of t above 2.31 constitute a statistically 
significant result, (*).
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Figure 2:8 demonstrates the results of table 2:9
graphically where the a decrease in receptor viability
with time is seen by a decrease in the gradient of the
standard curve. This is presumed to be due to disruption
of the proteins which form the receptors which decreases
their ability to bind with the ligand/radioligands. Line
A represents the average of results from weeks 1 to 4 and
indicates no loss of receptor viability up to 28 days
after receptor preparation. After this period there is a
significant decrease in the C /C values leading to
o x
shallower curves, line B = week 5 and line C = week 6.
Therefore the maximum time period for preparing 
receptors prior to use was set at 4 weeks. Rat brain 
tissue stored for 12 months at -20°C, prior to 
homogenisation, gave a curve consistent with that for 
weeks 1 to 4, as shown in figure 2:8, provided the 
prepared receptors were used within 2B days. Whole rat 
brains can therefore be stored at -20°C for at least a 
year with no loss of binding ability. The 3 dimensional 
structure of the receptors is retained when the whole 
brains are frozen down immediately they are excised. 
Storage time of prepared receptors is reduced to 4 weeks 
as the action of preparation disrupts the tissue 
surrounding the receptors thus increasing their fragility.
Results from the specific binding v. time 
experiment shown in table 2:12 and by figure 2:9, indicate 
the length of time required by the receptors and 
radioligand/ligand to reach equilibrium.
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Figure 2:8 A series of triazolam standard curves which
demonstrate the decrease in gradient with time.
25
20
15
10
5
0
10 30 40 50200
Triazolam concentration (ng/ml)
A - Results from weeks 1 to 4. 
B - Results from week 5.
C - Results from week 6.
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Table 2:12 DPM Results for Each Time Interval Between t0  
and tiOO-
Time Average DPM
(minutes)_______________________________
0.0 343.9
15.0 355.3
30.0 364.8
45.0 366.7
60.0 370.5
75.0 375.0
90.0 3 6 8.6
105.0 368.4
120.0 3 68.6
135.0 370.4
150.0 372.4
165.0 399.0
180.0 431.3
195.0 494.0
210.0 357.2
225.0 349.6
240.0 332.5
255.0 357.2
270.0 410.4
285.0 406.6
300.0 391.4
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Figure 2:9 Demonstration of the equilibrium disruption
with time when incubated at 25°C.
500
Sb
400
Period where the 
equilibrium is stable
300
200
240-180 300120600
Incubation time (minutes)
Sb - Specifically bound tritiated flunitrazepam
(DPM/assay).
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They also reveal how long the incubates could be 
left before the equilibrium began to disrupt and also how 
it can be reversed by the addition of excess unlabelled 
ligand. Once defrosted the BZ-R remain viable up to three 
hours, at room temperature, after which they begin to 
degenerate. This time scale allows an assay to be set up, 
incubation to take place and the bound and free fractions 
to be separated, providing the assay is begun immediately 
the BZ-R have completely defrosted.
N.B. Any attempt to speed up the BZ-R defrosting with 
warm or hot water will disrupt the integrity of the BZ-R.
The results in table 2:13, also shown in figure 
2:10, demonstrate the time period to reach equilibrium 
between the receptors and the radioligand and how it can 
be reversed by excess unlabelled ligand.
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Table 2:13 DPM Results for Time Intervals Between t0 and 
t \xo •
Association Curve 
Time average DPM 
(minutes)
Dissociation Curve 
Time average DPM 
(minutes)
0.0 138 .7 65.0 375 . 2
5.0 381.9 70.0 108 . 3
10.0 383 . 8 75.0 100 .7
15 .0 454. 1 80.0 60. 8
20.0 431.3 85.0 57 . 0
25.0 418 .0 90.0 55 . 1
30.0 431.3 95.0 49 . 4
35.0 437.0 100.0 47 . 5
40.0 389.0 105 .0 70 . 3
45.0 402 . 8 110.0 51. 3
50.0 418 .0 115 .0 53 . 2
55.0 446 . 5 120.0 45 . 6
60.0 456.0
The association curve shows that over 90% of the
radioligand is bound after 20 minutes and that the
equilibrium between the receptors and the ligand remains 
constant up to 60 minutes. The addition of excess 
triazolam displaces 95% of the radioligand within 5 
minutes reaching NSB levels after 10 minutes. Excess
Figure 2:10 Association and dissociation curves for
tritiated flunitrazepam and benzodiazepine 
receptors incubated at 25°C.
Addition of lug/ml triazolam
400
Sb
300
200
100
80 100 120604020
Incubation time (minutes)
Sb - Specifically bound tritiated flunitrazepam
(DPM/assay).
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triazolam is added at t „ as this falls within the
60
stable period of the equilibrium. If it had been added 
towards the end of this period, reversal might have been 
attributed to the start of the equilibrium disrupting as 
well as by the additional triazolam. From these two 
experiments the incubation period for a BZ-RRA can be set 
at 30 minutes minimum and 150 minutes maximum. This two 
hour period were the equilibrium is stable is sufficient 
to filter large numbers of samples before the 
receptor/ligand binding is disrupted.
Separation of the bound and free radioligand by 
filtration was used throughout, and the NSB reduced by 
washing the filters. As increased volumes of assay buffer 
were used to wash the filters, there was a corresponding 
decrease in the ± values. When the filters were washed 
with 5 and 10ml, these limits were approximately the 
same. Accordingly a volume of 5 x 1ml was used for 
susequent RRA as this enabled the NSB to be minimised 
whilst keeping the separation time as short as possible. 
Table 2:14 lists the compiled results for each of the 
filter/washing experiments, each result is the average of 
three experiments carried out in duplicate.
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Table 2:14 Results from Washing the Filters with Varying 
Volumes of Assay Buffer.
Wash (ml) 1.0 3.0 5.0 10. 0
Triazolam DPM DPM DPM DPM
(ng/ml)
0.0 962 . 3 823 . 6 953 . 2 967 . 2
±55.1 ±52 . 4 ±11. 6 ±13 . 7
1.0 789 . 4 680. 2 866 . 8 842 . 0
±63 . 1 ±94 .0 ±12.0 ±15 . 6
5.0 780. 9 566 .2 826 . 6 871.0
±24 . 2 ±40.3 ±17 . 8 ±15.4
10.0 626 .0 561.4 616 .7 572.9
±73 . 8 ±14 . 7 ±17.3 ±12 . 7
15.0 531. 1 430. 3 442 . 4 467. 6
±65 . 8 ±17 .4 ±19 . 6 ±17 . 8
25.0 453 . 1 348 . 6 332 . 6 293 . 5
±41. 6 ±4 . 03 ±7 . 4 ±16 . 2
50.0 128 . 2 212 . 8 120.1 117 . 3
±32 . 2 ±20 . 1 ±10 . 4 ±3 . 3
RRA results from the assay of various
benzodiazepines were graphed in order to obtain the K.
i
values. The results from three examples bromazepam.
flunitrazepam and triazolam, are shown in table 2:15 and
plotted out in figure 2:11.
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Table 2:15 Three Examples of Benzodiazepines used to
Determine K. Values.
1
Concentration
logioM
Percentage of 
specif ically 
Bromazepam
[3 ]FNZ 
bound. 
FNZ Triazolam
-9 101 91 75
-8 . 3 94 76 40
-8.0 96 64 18
-7.7 90 42 8
-7.3 87 31 5
-7 .1 74 26 3
-7.0 78 23 2
-6.7 51 18 1
-6.0 20 - -
The standards are calculated as a percentage of the
3zero standard to give the % of [ H]FNZ specifically-
bound to the receptors. From IC50 values, values
are calculated which indicate the potency of a particular
3
drug to displace [ HjFNZ from the receptors. The IC_0
b u
and values for the benzodiazepines assayed are given
in Table 2:16 and follow published trends.
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Figure 2:11 Curves demonstrating the concentration of
benzodiazepine to cause 50% inhibition of 
tritiated flunitrazepam binding to the 
receptors.
100
Percentage of 
tritiated FNZ 
specifically 
bound
50
-5-7 -6-8-9
-log of the benzodiazepine concentration (M)
A - Bromazepam.
B - Flunitrazepam. 
C - Triazolam.
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Table 2:16 IC__ and K. Values for a Selection of 
------------ 50 l
Benzodiazepines.
Benzodiazepine 1C M 
50
K. nM
1
Alprazolam 1.8xlO-8 12 . 2
Bromazepam 2.2xl0“7 149 . 6
Clonazepam 1.3X10-8 8 . 8
Diazepam 7.6xl0— 8 51.7
Desmethyl Diazepam 2.3xl0-7 156.4
3-OH-Diazepam l.oxio-7 68 . 0
Flunitrazepam (FNZ) 1.4X10-8 9 . 5
Desmethyl FNZ 2.5xl0~ 8 17 . 0
7-amino FNZ 3.9xl0_ 6 2700.0
Lorazepam 1.0X10-8 6 . 8
Nitrazepam 8.7xl0~8 59 . 1
Oxazepam 3.4xl0~7 231.0
Triazolam 2.7xl0-9 1.8
1-OH Triazolam 3.2xl0~ 8 21.7
4-OH Triazolam 6.9xl0-8 46 . 9
Ki = IC50/(1 + C/V
C = Concentration of [3H]FNZ - l.llnM. 
Kd  = 2.34 n M .
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Similar assays were carried out with a cross 
section of non-BZ, representing most pharmaceutical
classes, to investigate their lack of cross reactivity.
Of all the drugs assayed only caffeine and amphetamine
showed any icross reactivity, at levels of 25ug/ml and over
as seen in table 2:17 and 2:18 and by figures 2:12 and
2:13.
Table 2: 17 Diazepam Control Curve.
Drug Average DPM C C /C 
x o x
Diazepam
(ng/ml)
0.0 635.4 565 . 2
10.0 473 .4 403.2 1.4
25.0 457.2 387.0 1.46
50.0 297 .0 226.8 2.49
100.0 199 . 8 129.6 4.36
200.0 141.7 71.5 7.9
NSB 70.2
N.B. Diazepam NSB result used to calculate C x values 
for caffeine and amphetamine.
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Table 2 i18 Non-benzodiazepine Results.
Drug Average DPM
Caffeine
(ug/ral)
1.0
5.0 
10.0
25.0
30.0
45.0
50.0
730.8 
669.6 
58 5.0 
549 .0 
516 .6 
484.2 
477 .0
660.6 
599.4 
514 . 8 
478 . 8 
446 . 4 
414 . 5 
406 . 8
C /C 
O X
0.85
0.94
1.09
1.18
1.26
1.36
1.39
Amphetamine
(ug/ml)
1.0 572.4
5.0 558.0
10.0 491.4
25.0 442.8
30.0 415.8
45.0 383.4
50.0 406.8
502 .2 
487.8 
421.2 
372 . 6 
345 . 6 
313 . 2 
336 .6
1.12
1.16
1.34
1.51
1.63
1.80
1.68
As the BZ-RRA is used to detect benzodiazepines in the ng 
range, any other drugs present would need to have a very 
high concentration in order to interfere with the assay.
Figure
C /C o' x
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:12 RRA results indicating slight cross reaction
between caffeine and BZ-receptors above 25ug/ml.
5
4
3
2
1
0
40 120 16080 2000
Diazepam concentration (ng/ml)
\ ■______ i______ i______ i______ i-------1------ 1------ 1------ 1----- _i
0 10 20 30 40 50
Caffeine concentration .(ug/ml)
A - Diazepam. 
B - Caffeine.
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Figure 2 il3 RRA results indicating slight cross reaction
between BZ-receptors and amphetamine, 2 5ug/ml 
and above.
C /C o x
5
4
3
2
1
0
40 120 16080 2000
Diazepam concentration (ng/ml)
0 10 20 30 40 50
Amphetamine concentration (ug/ml)
A - Diazepam.
B - Amphetamine.
2:5 Conclusions
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This chapter has covered the various parts of the 
RRA, setting out the areas which have to be investigated 
in order to establish a RRA. A working protocol can now 
be drawn up for the BZ-RRA, which is the protocol followed 
when the greyhound urine samples were assayed for either 
triazolam or flunitrazepam. The method is easy to set up 
and the results can be manipulated to provide 
pharmacokinetic and statistical data.
Protocol
400ul Receptor preparation - Img/ml of protein. 
lOOul [3H]FNZ - SOnCi^.
50ul Standard or sample.
Vortex
Incubate for 30 minutes, 25°C.
Separate bound and free fractions by filtration.
Wash filters with 5 x 1ml assay buffer.
Place in Pico vials and add 4ml scintillant/vial.
Shake vigorously to disperse filter in scintillant.
3Count DPM of bound [ HJFNZ for 1 minute.
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Standards: Triazolam - 0, 1, 5, 10, 25, 35, 50ng/ml.
in drug Flunitrazepam - 0, 10, 25, 50, 100, 200ng/ml,
free urine.
For each assay a standard curve was established
with the appropriate standards, plus zero standards - 50
ul assay buffer, and NSB standards. All the standards and
samples are assayed in. duplo. The results are expressed
as C /C . C /C for the standards graphed against 
o x o x
concentration (ng/ml) gives a straight line with a 
reproducible gradient, as shown by graph 2:1. From this
the concentrations of triazolam or flunitrazepam in the
urine samples can be estimated.
As increasing numbers of standard curves were 
prepared the gradients were collated and statistically 
analysed to provide the limits within which the line must 
lie. Any line whose gradient is outside of these limits 
cannot be used to determine benzodiazepine concentrations 
in greyhound urine samples. The usual cause of this is 
the degradation of the standards with time. To prevent 
this, the standards were made up at the start of each week 
and stored at 4 to 6°C. Below is the gradient data 
collated from RRA of the greyhound urine samples:
Triazolam standard curves 
n = 62 x = 0.48, limits = 0.1.
Flunitrazepam standard curves 
n = 9 x = 0.06, limits = 0.008.
CHAPTER THREE
Analysis of Greyhound Urine Samples for Selected
Benzodiazepines______ by______ Radioreceptor______ Assay______ and
Radioimmunoassay.
3 :1 Introduction
The benzodiazepine-greyhound studies involved the 
collection of urine samples following single oral dosing 
of each greyhound with a benzodiazepine. Prior to dosing 
a blank urine sample was collected and during the study 
any behavioural changes by the greyhounds, such as
drowsines, were noted. A pilot study was carried out with 
diazepam to establish the dosing, sample collection and 
analysis procedures. Once the experimental procedures had 
been established, the main trials were carried out with
triazolam and flunitrazepam.
Triazolam and flunitrazepam were studied as they
are relatively new to the pharmaceutical market and
consequently there is little information regarding their 
effect on dogs, especially greyhounds. As they are more 
potent than the more established benzodiazepines, lower 
dosage forms can be used to obtain the required response 
[155]. Examples of the varying doses prescribed are shown 
in table 3:1:
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Table 3:1 A Variety of Benzodiazepines and their Active 
Metabolites Illustrating Differences in 
D o s a g e .
Benzodiazepine To treat Dose (mg) t., (hours)
7a
(man)
Triazolam Insomnia 0 .25 1.5 - 3
FNZ Insomnia 0.5 to 1.0 10 - 70
Nitrazepam Insomnia* 5.0 to 10.0 18 - 38
Diazepam Insomnia* 6.0 to 30.0 20 - 100
Desmethyl diazepam 40 - 100
CPXa Insomnia* 30.0 5 - 3 0
Demoxepam*3 1 4 - 9 5
Desmethyl diazepam0 40 - 100
a - Chlordiazepoxide.
b e  • •& - Chlordiazepoxide metabolites.
* - Causes daytime sedation due to a long half-life.
The smaller effective doses of triazolam and 
flunitrazepam result in lower amounts available in urine 
samples for detection by laboratories. Also the time 
scale during which urine samples, containing evidence of 
the drug, can be collected is less due to the much shorter 
half-lives of triazolam and flunitrazepam. Therefore 
sensitive analytical methods are required to detect these 
benzodiazepines in greyhound urine samples.
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Before the urine samples could be analysed, three 
additional experimental methods had to be established and 
evaluated:
a) Hydrolysis of the urine samples.
b) Extraction of the benzodiazepines and their
metabolites from the unhydrolysed and hydrolysed 
urine samples.
c) Radioimmunoassay (RIA), of both the unhydrolysed
and hydrolysed urine samples, to confirm the
presence of benzodiazepines.
Radioreceptor assay of samples detects only the 
benzodiazepine and its phase I metabolites, which are 
pharmacologically active. The assay will not detect any 
phase II metabolites conjugated as the glucuronide or
sulphate, or any phase I metabolites which are not
pharmacologically active. With the purpose of phase II 
metabolism being to increase the water solubility of the 
drug and its phase I metabolites, a high percentage of the 
dose excreted in the urine will be in the conjugated
form. Diazepam, triazolam and flunitrazepam conjugates 
are excreted in the urine as the following percentages of 
the total dose given:
Diazepam - approximately 70%.
Triazolam - approximately 80%.
Flunitrazepam - approximately 80%.
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Thus, conjugated as the glucuronide or the sulphate, rapid 
elimination of the drug from the body is ensured. The 
urine samples may contain some free parent drug and phase 
I metabolites at very low levels [87,156]:
Diazepam - trace amounts.
Triazolam - less than 1%.
Flunitrazepam - less than 1%.
As diazepam, flunitrazepam and triazolam 
metabolites are excreted mainly as the glucuronide, mild 
hydrolysis of the urine samples with /3-glucuronidase, 
from Helix pomatia was used to release the benzodiazepine 
metabolites from their conjugated form (157).
Extraction of benzodiazepines from biological 
samples is a logical step to obtain a more accurate 
assesment of the amount of drug present. In the case of 
RRA it generally involves the removal of protein
constituents which would interfere with ligand/BZ-R
binding. Three organic solvents were used to extract a 
series of benzodiazepine standards and the results
assessed to determine the viability of including this
extra step in the RRA. The three solvents were; methanol, 
chosen as it is the standard laboratory solvent to extract 
samples prior to radioimmunoassy, ethyl acetate 
(33,35,158,159,160,161,162,163,164) and dichloromethane 
(165, 166) .
Radioimmunoassay (RIA) was used as the second 
method to confirm the presence of diazepam, triazolam and 
flunitrazepam in the urine samples. It was chosen as it 
is both a well established and reliable analytical method, 
as well as being sufficiently similar to radioreceptor 
assay to allow confident comparison of the results (157).
The data generated by RRA and RIA of all 
unhydrolysed and hydrolysed urine samples from each 
triazolam and flunitrazepam greyhound study was collated. 
This enabled the benzodiazepine urine excretion profiles 
for triazolam and flunitrazepam plotted, which demonstrate 
the increase in metabolites detected by RRA and RIA after 
hydrolysis.
The data generated during the
triazolam/flunitrazepam greyhound trials also enabled 
limmited pharmacokinetic studies to be carried out. 
Pharmacokinetics enables the breakdown of the physical 
processes of drug absorbtion, distribution and elimination 
to be expressed as mathmatical functions involving time 
and concentration. Such data is used by doctors and 
pharmacists to predict the effect of a particular dose of 
a drug and to obtain correct dosing regimes. Should the 
intervals between doses become too long, the drug 
concentrations at the site of action will repeatedly fall 
below effective levels. If the dose is repeated too 
frequently though and the concentration of the drug will 
increase to toxic levels and have a detrimental effect.
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The benzodiazepine results for each set of hourly 
samples obtained by both assay methods were compared 
statistically by the paired t-test [154], This particular 
test was used as the samples contained substantially 
different amounts of the benzodiazepine given depending on 
the time of collection and the volume collected. Usual 
statistical methods whereby the means of two samples are 
compared cannot be used due to the large differences in 
the results which make significant variations between the 
means difficult to detect. By looking at the difference 
between pairs of results at each time interval and by 
adopting a null hypothesis approach, it is possible to 
test whether the means of the differences significantly 
differ from zero.
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3:2 Materials
Triazolam Tablets Donated by Messrs. Upjohn Ltd.
0.2 5mg
Flunitrazepam Donated by Messrs. Hoffmann-La Roche
Tablets, lmg
/3-Glucuronidase Obtained from Sigma Chemical Company® 
U.S.A.
90,000 13-glucuronidase units/ml,
400 sulphatase units/ml.
Emit®
d.a.u.™
BZ Assay kit
Obtained from Syva Company.
Sheep serum Scottish Antibody Production Unit, 
Law Hospital, Lanarkshire.
Donkey-
anti-Sheep
antibody
Scottish Antibody Production Unit, 
Law Hospital, Lanarkshire.
Assay Buffer 
throughout
25mM sodium phosphate buffer, pH 7.4
All other chemicals and solvents were of analytical grade.
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3:3 Methods 
3:3:1 Hydrolysis
Aliquots of each urine sample were hydrolysed as 
follows:- 2ml aliquots of each urine sample were placed 
in glass screw top vials with 0.5ml, 0.1M, sodium acetate 
buffer, pH 5 and 20ul fi-glucuronidase. After thorough 
mixing the vials were incubated for 24 hours at 37°C. 
The enzymic activity was stopped after this period by 
freezing the contents of each vial. These hydrolysed 
urine samples were stored at -20°C together with the 
unhydrolysed samples.
3:3:2 Sample Extraction
Diazepam and triazolam standards were prepared with 
drug free greyhound urine and extracted with each of the 
three solvents: methanol, ethyl acetate and
dichloromethane. The range of standards were:
Diazepam - 0, 10, 25, 50, 100, 200ng/ml.
Triazolam - 0, 1, 5, 10, 15, 20, 25, 35, 50ng/ml.
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Method
The standard was extracted in duplicate by adding
0.5ml of each to 2ml of solvent. After thorough mixing
and centrifugation, the organic layer was removed and
evaporated to dryness. When required for assay the
standards were reconstituted with 0.5ml of assay buffer.
The reconstituted standards were assayed together
with unextracted diazepam or triazolam urine standards,
which acted as controls. The results were plotted as
C /C against benzodiazepine concentration. This
o x
enabled plots of the extracted standards to be visually 
compared with those of the controls.
3:3:3 Radioimmunoassay
Both the hydrolysed and unhydrolysed urine samples 
were analysed by this method. A reagent solution was 
prepared by mixing equal volumes of the following:
1 0.05M sodium bicarbonate buffer, pH 9.0.
2 [3H]FNZ 50nCi.
3 Benzodiazepine specific antibody (4% solution), 
from the EMIT & BZ assay kit.
4 A 0.125% solution of sheep serum.
Standards - all made up in drug free greyhound urine. 
Diazepam - 0, 10, 25, 50, 100, 200ng/ml.
Triazolam - 0, 1, 5, 10, 15, 20, 25, 35, 50ng/ml.
Flunitrazepam — 0, 10, 25, 50, 100, 200ng/ml.
- 92 -
Method
LP3 tubes were set up in duplicate, one pair for 
each standard or sample and the following constituents of 
the assay were added to each: 500ul reagent solution,
lOOul standard or sample and 200ul of donkey anti-sheep 
antibody (12.5%) solution. The tubes were vortexed and 
incubated overnight at 4°C. To separate the bound and 
free fractions the tubes were centrifuged at 3000rpm for 
15 minutes.
400ul of the supernatant was removed and thoroughly 
mixed with 4ml of scintillant in a Pico vial and counted 
for 1 minute to determine the DPM for each standard or 
sample. A plot of standard DPM against benzodiazepine 
concentration gave a calibration curve could be used to 
determine the benzodiazepine concentrations in the 
samples. The resulting curve is linear over the standard 
range used and enables the sample concentrations, in 
ng/ml, to be read directly from the curve.
The total amount of radiolabel available, the total 
counts, was estimated by the addition of 125ul of label to 
675ul buffer, with incubation and separation as for the 
standards. The percentage binding was estimated by the 
following equation:
% binding = 1 - Onq/ml CPM x 100
Total CPM
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3:3:4 Pharmacokinetics of Urinary Excretion - Calculation 
of the Elimination Rate Constant and Half-Life
Renal clearance is the rate of filtration plus the
rate of secretion of urine, minus the rate of aqueous
reabsorbtion by the kidney. Glomerular filtration and
diffusion is a first order process so the rate of transfer
of drug is related to its concentration in the plasma
which in turn is related to the concentration of the drug
in the body. The appearance of the drug in the urine
reflects its disapperance from the plasma/body. It was
not possible to obtain complete urinary excretion data for
some of the greyhound trials. Due to either the absence
of, or incomplete collection of samples. A semi-log plot
of A D u M t  against time was used to estimate the
elimination rate constant (k ..) and therefore calculate
el
the half-life (tya)-
It gives a straight line, the gradient of which
-k , / 2.3 03 and from this it is possible to calculate the 
el
half-life as t^ = 0.693/kel# as illustrated by
figure 3:1.
Du is the cummulative amount of drug excreted. 
This usually refers to the excretion of the parent drug, 
but in the case of triazolam and flunitrazepam it refers 
to the metabolites excreted as only a very small 
percentage of the parent drug is excreted.
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Figure 3:1 Illustration of a semi-log plot from which 
the elimination rate constant and the half 
life can be determined.
Log ADu 
10
Slope = -kel 
2.303
j_______ i i ,  i------- •------- 1------- 1
Time
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3:3:5 Statistical Comparisons
A paired t-test was used to test whether the mean 
of the difference between each set of results compared 
differs significantly from zero [154]. The following sets 
of results were statistically compared:
1 Triazolam
a Unhydrolysed RIA and hydrolysed RIA.
b Unhydrolysed RRA and unhydrolysed RIA.
c Hydrolysed RRA and hydrolysed RIA.
d Unhydrolysed RRA 1 and Unhydrolysed RRA 2.
e Hydrolysed RRA 1 and hydrolysed RRA 2.
2 Flunitrazepam
a Unhydrolysed RIA and hydrolysed RIA.
b Unhydrolysed RRA and unhydrolysed RIA.
c Hydrolysed RRA and hydrolysed RIA.
N.B. RRA 1 refers to urine samples assayed within 2 days
of collection.
RRa 2 refers to samples assayed after being stored 
at -20°C for 12 months.
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3:4 Protocol for Greyhound Trials
The following benzodiazepines were used to dose the 
greyhounds:
Diazepam 1 x 5mg tablet.
Triazolam 1 x 250ug tablet or 2 x 250ug tablets.
Flunitrazepam 1 x lmg tablet or 2 x lmg tablets.
A blank urine sample was collected from each 
greyhound prior to oral dosing with one of the three BZ 
selected. Subsequent urine samples were collected at the 
following hourly intervals:
l f 2, 3, 4, 5, 6, 7, 24, 25, 26, 27, 28, 29, 30, & 31.
The samples from each BZ-greyhound trial were
treated and assayed as follows:
1 After collection, the total volume of each sample 
was measured and recorded.
2 2ml of each sample was removed and subjected to
enzymic hydrolysis.
3 The remainder of each sample was aliquoted into 5ml
volumes for analysis by RRA and RIA.
4 The unhydrolysed and hydrolysed samples were stored
at -20°C until required for analysis.
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3:5 Results and Discussion
3:5:1 Hydrolysis of the Urine Samples
Mild hydrolysis with 13-glucuronidase increases 
the concentration of pharmacologically active components 
available to interact with the BZ-R which effectively 
makes the assay more sensitive. It also enables 
benzodiazepine metabolites to be detected in samples 
collected up to 24 hours after dosing. This is an 
important factor in the analysis of samples from race 
tracks as the greyhound may have been dosed prior to 
arrival at the track.
Diazepam is excreted in the urine as the parent 
compound only in trace amounts. The majority, 70%, of the 
dose is excreted as the metabolites: N-desmethyl
diazepam, 3-hydroxy diazepam and 3-hydroxy-desmethyl 
diazepam. The latter two are prescribed in their own 
right as the tranquillizers temazepam and oxazepam. 
Figure 3:2 illustrates the metabolic pathway of diazepam. 
The majority of the excreted metabolites are in the urine 
conjugated with glucuronic acid. Also the urine samples 
contain a small percentage of non-pharmacologically active 
metabolites which are not detected by the RRA. The 
increase in compounds detectable by BZ-RRA is demonstrated 
by figure 3:3 which plots an example of an excretion 
profiles of diazepam, both before and after hydrolysis. 
The corresponding RRA results are given in table 3:2 below.
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Figure 3:2 The metabolic pathway of diazepam.
Diazepam
Cl
f H*N-Cn
C=N/
CHOH
Desmethyl diazepam
Cl
H ^0 
N-Cs
c=n c^hoh
3-hydroxy diazepam 3-hydroxy-
desmethyl diazepam
+ conjugates
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Table 3:2 RRA Results for Urine Samples Collected after 
Dosing the Greyhound with 5mg of Diazepam.
Time after 
dosing (hrs)
Diazepam ng/ml 
Unhydrolysed Hydrolysed
1 0.0 132 . 0
2 0.0 668 .0
3 0.0 564 . 0
4 0.0 192 . 0
5 0.0 164 . 0
6 0.0 208 . 0
7 0.0 60 . 0
24 0.0 100.0
25 0.0 28 . 0
26 0.0 0 . 0
27 0.0 0 . 0
28 0.0 0.0
29 0.0 0.0
30 0.0 0.0
31 0.0 0.0
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Figure 3:
Diazepam
(ng/ml)
3 An example of an excretion profile for diazepam,
both before and after hydrolysis.
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The main metabolic pathway to remove triazolam from
the body is by hydroxylation and its major metabolites are
l'-hydroxy triazolam and 4-hydroxy triazolam. 80% of a
dose of triazolam is excreted in the urine with the
remainder being lost via the faeces. To date nine
triazolam metabolites have been found in dog urine
[85,87]. The metabolic pathway of triazolam and its major
metabolites is shown in figure 3:4. In addition to the
major metabolites, the following minor metabolites have
also been identified:
1',4-hydroxy triazolam, 1-desmethyl triazolam,
2 monohydroxy analogues + a dihydroxy, a
monohydroxymonomethoxy and a dihydroxymonomethoxy
triazolam analogue.
These minor metabolites make up around 10% of the
triazolam excreted in the urine, though not being
pharmacologically active they are not detected by RRA.
They were originally identified by administering
14[ C J t n a z o l a m  followed by TLC and autoradiography of 
the urine samples. Further identification was made by 
GC-MS of the various fractions. Tables 3:3 and 3:4 
contain examples of radioreceptor assay results following 
oral dosing with either 0.25 or 0.5mg of triazolam.
Figures 3:5, 3:6, 3:7, 3:8, 3:9 and 3:10 show the
excretion profiles of triazolam and its metabolites, both 
before and after hydrolysis plotted from the data given in 
tables 3:3 and 3:4.
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Figure 3:4 The metabolic pathway and major metabolites 
of triazolam.
Cl
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triazolam
OH
'jQgr
Cl
Dic h l o r o -
tri a z o l y l -
b e n z o p h e n o n e
Cl =0
1 ' -hydroxy
triazolam
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Table 3:3 Three Sets of Radioreceptor Assay Results for 
Urine Samples Collected after Dosing the 
Greyhound with 0.25mg of Triazolam.
Time after 
dosing (hrs)
1
U/H
(ng/ml) 
H
2
U/H
(ng/ml) 
H
3
U/H
(ng/ml) 
H
1 . 7.0 7 .0 2 . 0 10.0 5.0 0.0
2 12 . 5 212 . 5 2 . 5 23 . 0 6.0 65.0
3 9 . 5 12. 5 2 . 0 21.0 5 . 5 14 . 5
4 8 . 0 50 . 0 2 . 0 13 . 5 5.0 6 . 5
5 8.0 40.0 2 . 0 8 . 0 5 . 0 6.0
6 8 . 5 70.0 2 . 0 14 . 5 5.0 6 . 0
7 - - - - 0.0 6.0
24 7.5 28 . 5 2 . 0 6 . 5 5.0 5.7
25 7 . 5 27 . 5 0 . 0 0.0 5 . 5 5 . 5
26 7 . 5 10. 5 0.0 0.0 5 . 5 0.0
27 - - 0 . 0 0.0 0.0 0.0
28 0.0 0 . 0 0 . 0 0.0 0.0 5 . 5
29 1.5 0.0 0.0 0.0 - -
30 - 0 . 0 0.0 0.0 0.0
31 0.0 0 . 0 - - 0.0 0.0
- no sample collected.
U/H - Unhydrolysed urine sample. 
H - Hydrolysed urine sample.
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Figure 3:
Triazolam
(ng/ml)
5 Excretion profile 1 following a single oral
dose of 0.25mg of triazolam.
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Figure 3:6
Triazolam
(ng/ml)
Excretion profile 2 following a single oral
dose of 0.25mg of triazolam.
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Figure 3:7
Triazolam
(ng/ml)
Excretion profile 3 following a single oral
dose of 0.25mg of triazolam.
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Table 3:4 Three Sets of Radioreceptor Assay Results for 
Urine Samples Collected after Dosing the 
Greyhound with 0.5mg of Triazolam.
Time after 1 (ng/ml) 2 (ng/ml) 3 (ng/ml)
dosing (hrs) U/H H U/H H U/H H
1 10. 5 210.0 3 . 2 110.0 13 . 0 112 . 5
2 4 . 5 62 . 0 2 . 2 42 . 5 6 . 0 53 . 7
3 0.0 27 . 5 1.5 12 . 5 0 . 0 37 . 5
4 0.0 7.5 0.0 6 . 2 0.0 5 . 5
5 0.0 7.0 0 . 0 9.7 0.0 2 . 0
6 0.0 21.5 0.0 18 . 5 0.0 2 . 5
7 0.0 16 . 5 0.0 6 . 5 0.0 2.0
24 1.5 5 . 5 1.5 5 . 5 0.0 2.0
25 0.0 5.0 0.0 0.0 0.0 0.0
26 0.0 0.0 0 . 0 2 . 0 0.0 0.0
27 0.0 0.0 0.0 0 . 0 0 . 0 0.0
28 0.0 0.0 0.0 0 . 0 0.0 0.0
29 0 . 0 0.0 0.0 0.0 0.0 0 . 0
30 0.0 0.0 0 . 0 0.0 0.0 0.0
31 0.0 0.0 0 . 0 0.0 0.0 0.0
- no sample collected.
U/H - Unhydrolysed urine sample. 
H - Hydrolysed urine sample.
-  108 -
Figure 3:
Triazolam
(ng/ml)
Excretion profile 1 following a single oral
dose of 0.5mg of triazolam.
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Figure 3:
Triazolam
(ng/ml)
Excretion profile 2 following a single oral
dose of 0.5mg of triazolam.
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Figure 3
Triazolam 
(ng/ml)
:10 Excretion profile 3 following a single oral
dose of 0.5mg of triazolam.
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Flunitrazepam is excreted in the urine as desmethyl 
flunitrazepam and 7-amino flunitrazepam, its major 
metabolites which are pharmacologically active. Less than 
1% of that excreted in the urine is as unchanged parent 
drug. The metabolic pathway of flunitrazepam is shown in 
figure 3:11. Other minor metabolites excreted in this way 
include:
3-hydroxy flunitrazepam.
3-hydroxy-7amino flunitrazepam.
7-amino-l-desmethyl flunitrazepam.
7-acetamido flunitrazepam.
The metabolites excreted in the urine constitute 
90% of the dose with the remaining 10% excreted in the 
faeces. Tables 3:5 and 3:6 contain a selection of 
receptor assay results following oral dosing with either 
1.0 or 2.Omg of flunitrazepam. Figures 3:12, 3:13, 3:14,
3:15, 3:16 and 3:17 show the excretion profile for
flunitrazepam, both before and after hydrolysis, for both 
dose levels.
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Figure 3:IX The metabolic pathway of flunitrazepam.
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Table 3:5 Three Sets of Radioreceptor Assay Results for 
Urine Samples Collected after Dosing the 
Greyhound with l.Omg of Flunitrazepam.
Time after 
dosing (hrs)
1
U/H
(ng/ml) 
H
2
U/H
(ng/ml)
H
3
U/H
(ng/ml)
H
1 0 . 0 33 . 0 4 . 0 2 . 0 0 . 0 26 . 5
2 9 . 0 60.0 6 . 0 22.0 0.0 296 . 0
3 0.0 0.0 4 . 0 14 . 0 0 . 0 366 .0
4 0 . 0 11.0 4 . 0 11. 0 15 . 5 1276 . 0
5 8 . 0 0 . 0 2 . 0 5 . 0 0 . 0 141.0
6 0.0 0.0 4 . 0 15 . 0 0 . 0 61.0
7 0.0 0.0 4 . 0 17 .0 0.0 61.0
24 9.0 9 . 0 7.0 8 . 0 0.0 2.8
25 0.0 0.0 4 . 0 8 . 0 0.0 0.0
2 6 0 . 0 0 . 0 0 . 0 0.0 0 . 0 0.0
27 0.0 0 . 0 0 . 0 0.0 0.0 0.0
28 0.0 0.0 0 . 0 0 . 0 0.0 0.0
29 0.0 0.0 0 . 0 0 . 0 0 . 0 0.0
30 0.0 0 . 0 0 . 0 0.0 0.0 0.0
31 0.0 0.0 0 . 0 0 . 0 0.0 0.0
U/H - Unhydrolysed urine sample. 
H - Hydrolysed urine sample.
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Figure 3: 12
Flunitrazepam
(ng/ml)
Excretion profile 1 following a single oral
dose of l.Omg of flunitrazepam.
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Figure 3:13 Excretion profile 2 following a single oral
dose of l.Omg of flunitrazepam.
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Figure 3:14 Excretion profile 3 following a single oral
dose of l.Omg of flunitrazepam.
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Table 3:6 Three Sets of Radioreceptor Assay Results for 
Urine Samples Collected after Dosing the 
Greyhound with 2.0mg of Flunitrazepam.
Time after 
dosing (hrs)
1
U/H
(ng/ml) 
H
2
U/H
(ng/ml) 
H
3
U/H
(ng/ml). 
H
1 0.0 4 . 2 67 . 0 103 . 0 0.0 1.5
2 26.7 1.5 10 . 0 280.0 - -
3 53 .3 570 . 0 10 . 0 66.0 0.0 143 .0
4 0.0 100.0 20 . 0 26 . 6 0 . 0 43 .0
5 0.0 60.0 0.0 95 . 6 0.0 103 .0
6 0.0 0.0 0.0 53 . 3 0.0 76 . 6
7 0.0 56.7 0.0 26.7 0.0 43 . 3
24 0.0 0.0 2 . 8 26.7 0 . 0 26 . 6
25 0.0 0.0 4 . 0 8 . 0 0.0 0.0
26 0.0 0.0 0 . 0 6 . 6 0.0 0.0
27 0.0 0.0 0 . 0 0.0 0.0 0.0
28 0.0 0 . 0 0.0 0.0 0 . 0 0.0
29 0.0 0.0 0 . 0 0.0 0.0 0 . 0
30 0.0 0.0 0.0 0.0 0.0 0.0
31 0.0 0.0 0 . 0 0.0 0.0 0.0
- no sample collected.
U/H - Unhydrolysed urine sample. 
H - Hydrolysed urine sample.
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Figure 3:15 Excretion profile 1 following a single oral
dose of 2.0mg of flunitrazepam.
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Figure 3:16
Flunitrazepam
(ng/ml)
Excretion profile 2 following a single oral
dose of 2.0mg of flunitrazepam.
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Figure 3:17
Flunitrazepam
(ng/ml)
Excretion profile 3 following a single oral
dose of 2.0mg of flunitrazepam.
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Though two different dose levels of triazolam and 
flunitrazepam were given to the greyhounds there was
little difference in the RRA results shown in tables 3:3, 
3:4, 3:5 and 3:6; and in figures 3:5, 3:6, 3:7, 3:8, 3:9, 
3:10, 3:12, 3:13, 3:14, 3:15, 3:16, and 3:17. Some
increase in the amounts of benzodiazepines detected had 
been expected, though as the greyhounds were not drowsy 
after either dose it follows that a much higher level 
would have to be given to see a significant increases in 
the RRA results.
As can be seen from the preceeding tables and
figures hydrolysis increases the amount of benzodiazepam 
metabolites available to interact with the BZ-R. Whereas 
conventional chromatographic methods, such as HPLC and 
G L C , seperate the parent drug and its metabolites into
individual peaks; RRA only measures the total amount of 
pharmacologically active components in each sample.
As it is known which benzodiazepine was given to 
each greyhound, it follows that the metabolites 
subsequently excreted in the urine can be predicted 
[5,12,155,167,168]. As the increase in the amount of 
benzodiazepine detected after hydrolysis is due only to an 
increase in pharmacologically active primary metabolites, 
released from the conjugates, it is possible to estimate 
what percentage of the increase is due to each metabolite.
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The values for triazolam, flunitrazepam and
their respctive metabolites are given below:
Triazolam 1.8nM.
l'-hydroxy triazolam 21.7nM.
4-hydroxy triazolam 46.9nM.
Flunitrazepam 9.5nM.
Desmethyl flunitrazepam 17.0nM.
7-amino flunitrazepam 2700.OnM.
They show that higher concentrations of the metabolites
3are required to displace [ HjFNZ than their parent
benzodiazepine. This was confirmed by a series of RRA
carried out with either flunitrazepam or triazolam as the 
standards and their appropriate metabolites as the 
samples. Thus the metabolites can be equated with their 
parent benzodiazepine in their ability to displace
[3H]FNZ. The results are given in tables 3:7, 3:8 and
3:9.
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Table 3:7 Triazolam Metabolite RRA Results Equated with
Triazolam.
Metabolite
(ng/ml)
Triazolam 
(ng/ml)
Triazolam
Equivalent
l 1-hydroxy triazolam 
75 
100 
200 
1000
5.2 
10. 3 
30.1 
101.0
average
69. 3 
103 .0 
150 . 5 
101.0 
105 . 9
4-hydroxy triazolam 
100 
200 
1000
1.8 
5 . 9 
72 . 9
18 . 0 
29 . 5 
72 . 9
average 40 . 0
106ng triazolam is equivalent to lOOOng of 1'-hydroxy 
triazolam.
Or 1'-hydroxy triazolam is approximately lOx less potent 
than triazolam.
40ng triazolam is equivalent to lOOOng 4-hydroxy triazolam. 
Or 4-hydroxy triazolam is approximately 25x less potent 
than triazolam.
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Table 3:8 Desmethyl Flunitrazepam RRA Results Equated
with Flunitrazepam.
Desmethyl FNZ FNZ FNZ
ng/ml ng/ml Equivalent
1 1.0 1000.0
5 2.2 440.0
10 9.6 960.0
25 18.6 744.0
50 32.2 644.0
75 47.0 627.0
100 118.4 1884.0
200 1742.0 8710.0
average 1876.0
lug flunitrazepam = 1.8ug desmethyl flunitrazepam.
Or desmethyl flunitrazepam is approximately 1.8x less 
potent than flunitrazepam.
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Table 3:9 7-amino Flunitrazepam RRA Results Equated
with Flunitrazepam.
7-amino FNZ FNZ FNZ
ng/ml ng/ml Equivalent
100
500
f.*
1000
2000
4000
5000
6000
8000
10000
2.6 
5 . 6 
4.2 
13 .0 
25 . 8 
46.4 
31.6 
37 . 4 
.46.5
260.0 
112 . 0 
42 .0 
65.0 
64 . 5 
92 . 8 
52 . 6 
46 . 7 
46 . 5
average 86.9
lOOOOng 7-amino flunitrazepam = 87ng flunitrazepam.
Or 7-amino flunitrazepam is approximately 115x less potent 
than flunitrazepam.
From the values and the
metabolite/benzodiazepine standard RRA graphs it is 
possible to determine the contribution made by each of the 
major metabolites to the amount of benzodiazepine detected 
after hydrolysis.
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To calculate the affinity of triazolam and FNZ metabolites 
in relation to their parent compound.
K i (nM)
Triazolam 1.8
l'-hydroxy triazolam 21.6
4-hydroxy triazolam 46.6
Ratio: triazolam:1'-hydroxy triazolam:4-hydroxy triazolam 
1 12 26
These results compliment those from the RRA results. 
Therefore presume that for every lg of triazolam detected, 
log and 25g of l'-hydroxy and 4-hydroxy triazolam are
detected.
K. (nM)
Flunitrazepam 9.5
Desmethyl flunitrazepam 17.0
7-amino flunitrazepam 2700.0
Ratio: flunitrazepam:desmethyl flunitrazepam:7-amino 
flunitrazepam
1 1.8 284
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These result compliment the RRA results in demonstrating
that this metabolite has ~ lOOx less affinity for the
benzodiazepine receptors than flunitrazepam or desmethyl
flunitrazepam. So for every lg of flunitrazepam detected,
\
1.8g of desmethyl flunitrazepam are detected.
To determine what percentage of the original dose 
is excreted in each sample, estimates of the contribution 
to the RRA result made by each benzodiazepine metabolite 
have to be made. The two major metabolites of triazolam 
have different affinities for the BZ-R so before 
recalculating the hydrolysis results, the proportion they 
are excreted in has to be known. From previous 
benzodiazepine trials with dogs, l'-hydroxy and 4-hydroxy 
triazolam are excreted in the proportions of 10:7.5. So 
for each hydrolysed triazolam urine sample, of the 
increase after hydrolysis, 57% is assumed to be due to 
l'-hydroxy triazolam with the remaining 43% assumed to be 
due to 4-hydroxy triazolam.
As the 7-amino flunitrazepam metabolite has lOOx 
less affinity for the receptors than flunitrazepam and 
desmethyl flunitrazepam, it was assumed that the higher 
concentrations detected were due only to an increase in 
the latter metabolite. Though both would become 
unconjugated during hydrolysis, desmethyl flunitrazepam 
would bind preferentially due to its higher affinity for 
the receptors. By using the assumption made above it is 
possible to recalculate the results after sample
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hydrolysis. This enables a more accurate picture of the 
greyhound excretion profiles of flunitrazepam and 
triazolam to be drawn. This was done as follows:
For a particular time interval the unhydrolysed RRA 
result was subtracted from the hydrolysed RRA result, thus 
giving the increase in metabolites (ng/ml). For 
triazolam, 57% of this increase was due to l'-hydroxy 
triazolam which has lOx less affinity for the BZ-R than 
triazolam; so 57% of the increase was multiplied by 10. 
The remaining 43% was due to 4-hydroxy triazolam which has 
2 5x less affinity for the BZ-R; So this percentage was 
multiplied by 25.
In the case of flunitrazepam only desmethyl 
flunitrazepam is considered and it has 1.8x less affinity 
for the BZ-R. Therefore the increase after hydrolysis was 
multiplied by 1.8. Examples for each benzodiazepine are 
given in tables 3:10 and 3:11 to illustrate the 
calculations made.
3:5:2 Extraction
Extraction of diazepam and triaolam by the three 
solvents involved a simple; though time consuming method. 
Examples of RRA results of extracted diazepam and 
triazolam standards are shown in tables 3:12 and 3:13.
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Table 3:12 Examples of Experimental Data from the r r a  of 
Control and Extracted Diazepam Standards.
C /C 0 X
Diazepam Control Methanol Ethyl Dichloro-
(ng/ml) Acetate methane
0 1.13 0 .93 1.19 1.22
10 1.34 1.35 1.18 1.78
25 1.94 1.79 1.41 1.66
50 2 .07 2 .96 1.74 2 .29
100 5.24 3.21 3 .93 3 . 40
200 9 .53 5 . 64 4 . 64 7 .32
Table 3:13 Examples of Experimental Data from the RRA
Control and Extracted Triazolam Standards.
C /C 
0 X
Triazolam Control Methanol Ethyl Dichloro-
(ng/ml) Acetate methane
0 0 .98 1.70 1.01 1.19
1 1.61 1.67 1.45 1.51
5 2 . 69 2 .74 2 . 47 2.14
10 6 .29 4 .95 5 .59 5 .29
25 10.78 8 .36 4 . 37 20 . 13
50 30.20 10 . 40 18 . 87 17 .76
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The three extracted sets of standards gave results which 
fell below those of the unextracted standards, as can be 
seen in figures 3:18 and 3:19. This is due to the 
proportional extraction of diazepam and triazolam by each 
organic solvent. The amount extracted is dependant on the 
solubility of the benzodiazepines in each solvent.
Diazepam and triazolam are equally soluble in the three 
solvents used in this experiment, though an unknown
benzodiazepine in a sample could have a different
solubility in the solvents and may not be extracted.
Repeated re-extraction of the a sample followed by 
pooling of the extracts increases the amount extracted, 
however 100% extraction can not be acheived. It is also 
time consuming, and detracts from the quick analytical 
method RRA was developed as. As extraction consistantly 
gave lower results, it was not included in the RRA of 
urine samples. Very turgid samples were centrifuged for 5 
minutes prior to assay to remove any proteins wwhich could 
cross react with the receptors (34, 38, 308).
Published papers refer only to extraction when 
plasma or whole blood is being analysed, usually only as a 
way of precipitating the protein fraction. Examples of 
such methods are as follows:
Addition of 2M perchloric acid followed by 
centrifugation, (29,30)
Addition of IN NaOH followed by extraction with 
ether, (31, 32 & 303).
Figure 3:18 An example of experimental data from RRA of 
control and extracted diazepam standards.
10
x
20 40 60 80 100 120 140 160 180* 200
Diazepam concentration (ng/ml)
A - Unextracted standards (controls).
B - Dichloromethane extracted standards. 
C - Methanol extracted standards.
D - Ethyl acetate extracted standards.
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Figure 3:19 An example of experimental data from RRA of 
control and extracted triazolam standards.
30
20
10
0
40 60 80 100 120 140 160 180 200200
Triazolam concentration (ng/ml)
A - Unextracted standards (controls).
B - Dichloromethane extracted standards. 
C - Ethyl acetate extracted standards.
D - Methanol extracted standards.
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3:5:3 Radioimmunoassay
Radioimmunoassay (RIA) is a well established 
routine method for the analysis of drugs in biological 
fluids. It is a very similar technique to RRA in that it 
depends on the competition between the drug and the 
radiolabelled drug for a binding site. They differ as 
with RRA the binding site is part of the receptor complex, 
where as with RIA it forms part of an antibody. The
outcome of each method is the same as the bound and free
labelled drug is separated, either by centrifugation or 
filtration, followed by either fraction being counted in
order to construct a standard curve. It is the antibody 
component of RIA which can present problems and which sets 
the two apart from each other. In order to establish the 
RRA method all that is required is an appropriatly 
labelled drug and a receptor preparation. The latter is
usually made from brain tissue as it contains all the 
receptors for the major drug groups.
To set up a RIA, the appropriate antibody has first
to be generated. This is done by injecting a low 
concentration of the drug into the animal, a sheep or 
rabbit, where it acts as an antigen and antibodies are 
raised against it. Often the molecular weight of the drug 
is too low to cause an immune response so it has to be
coupled to a larger protein, a hapten, usually albumin.
Once established, blood is withdrawn and the antibodies
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can be separated and stored until required. It is this 
time period which can hold up experiments, as it can take 
several weeks to raise the antibodies and to purify the 
serum enough for use. Purification is necessary as the 
antiserum requires a certain degree of specificity in
order that it only recognises the group of drugs to which 
it was raised. The antibody titre is generally high
enough that it can be serially diluted to a point where 
50% of labelled drug will bind to the antibodies.
The source of antisera can also affect the results 
as antibodies from different manufacturers will vary in 
the degree of specificity for the drug group required. By 
using commercial preparations of antisera from the same 
source for each assay it is possible to obtain
reproducible results. As RRA and RIA are similar 
analytical methods it was therefore possible to confirm 
the RRA results, that benzodiazepines are present in the 
urine samples, and to compare RRA and RIA results to 
demonstrate the specificity of each method for
benzodiazepines only.
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3:5:4 Diazepam Pilot Study
Diazepam was used to establish the greyhound trial
procedures as it is one of the most widely studied
benzodiazepines. There are many papers available relating 
to clinical studies and pharmacokinetics of diazepam 
[65,6 6,67,6 8,316 9,170,171,172,17 3,174,17 5]; also the
analysis of diazepam and its metabolites in plasma and 
urine: by TLC [176,177,178,179], GLC [180,181,182,183,184, 
185,186,187,189], HPLC [19 0,191,192,193,194,195,196],
RIA [172,197,198,199], and RRA [4,5,6,7,10,11].
As diazepam has a long half-life of 2 to 4 days it 
can be detected in urine samples, by RRA, up to 28 hours
after dosing. The relatively high recommended dose of 1
to 5 mg for children, [155], which was used to dose the 
greyhounds enables relatively easy detection of 
metabolites. As the majority of diazepam metabolites are 
pharmacologically active, this also increases the 
liklihood of the RRA detecting benzodiazepines in urine 
samples.
The greyhounds were not affected by the single oral 
5mg dose of diazepam in that they were not noticeably 
drowsy and there was no difficulty in collecting the 
samples. The dose remained at 5mg for the pilot study as 
at this level the metabolites could be easily detected by 
RRA and RIA.
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By carrying out four trials with diazepam, the 
whole experimental procedure from dosing the greyhounds to 
assaying the samples was tested out. It enabled any 
problems associated with the procedures to be ironed out 
before the main triazolam and flunitrazepam trials were 
begun. The dosing and sample procedure was kept simple 
and presented few problems, the main one being to persuade 
the dog to swallow the tablets. This was overcome by 
placing the tablets directly to the back of the greyhounds 
throat and encouraging it to swallow, rather than by 
mixing them in the food where they could be easily nosed 
out.
The daytime hourly sample collections were made 
easier by the use of a metabolic cage with the dogs being 
returned to their kennels overnight. Little sample was 
lost as the dogs did not foul their sleeping area and it 
was possible to collect a total overnight sample when the 
dogs were exercised first thing every morning.
As the greyhounds were accustomed to the sample 
collection procedure carried out at the race tracks by 
'dexterous use of a bowl1, this method was employed during 
the trials and caused little distress or discomfort. It 
also meant there was no need for cathaterisation. Though 
the dogs were kept in the metabolic cage during the day, 
they were exercised at hourly intervals which generally 
resulted in the sample being being collected. Each 
greyhound trial was carried out separatly to enable the 
animal nurses to focus their full attention on the
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particular dog being dosed, and also avoided any mix up 
with samples. It also enabled each greyhound to have a 3 
to 4 week recovery period between dosing which ensured 
there was no residual triazolam or f lunitrazepam in the 
dog when the next dose was given. With diazepam this
period between trials was extended to 6 weeks due to its 
longer half-life.
Once a full set of samples for a particular trial 
had been collected they were aliquoted in to 2 and 5 ml
portions. The 2 ml aliquot was hydrolysed according to 
the methods given in section 3:3:1 and the samples were 
stored at -20°C until they were required for assay.
As the diazepam dose was relatively large, this 
made it easy to set up a RRA for the samples. The
experimental procedures had already been established for 
the standards and spiked urine samples, so this pilot 
study presented a way of discovering any problems with the 
RRA of actual samples. In practice this proved to be no 
different to the RRA of standards/spiked samples. Any
samples which had excessive amounts of proteinaceous 
material and other particulate matter were centrifuged 
prior to assay. A blank urine sample was always taken 
prior to dosing so any variation between greyhounds as to 
possible cross reactivity with the RRA could be taken into 
account. The RRA result of the blank urine sample also 
served as a cut off point whereby any results below this 
result were taken as not containing any benzodiazepine.
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The samples from the diazepam trials were assayed 
both before and after hydrolysis and the results are shown 
in table 3:2 and figure 3:2. Figures 3:2 demonstrates 
how there is an increase in metabolites detected after 
hydrolysis. This is due to the release of the phase I 
metabolites from their glucuronide conjugates. The 
samples were also analysed by RIA which confirmed the 
presence of benzodiazepines in the urine. Table 3:14
lists a set of RIA results which constitute a standard 
curve, as an example, and figure 3:20 demonstrates them 
graphically.
Table 3:14 Example of Radioimmunoassay Results 
to Form a Diazepam Standard Curve.
Diazepam Average
(ng/ml) DPM
0 999
10 2545
25 3421
50 3544
100 3537
200 3861
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Figure 3:20 An example of a standard curve following 
radioimmunoassay of diazepam standards.
4000
x DPM
3000
2000
100O
20 40 60 80 100. 120 140 160 18C 2000
Diazepam standards (ng/ml)
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Once this pilot study had established a workable 
dosing regime and sample collection, followed by 
successful RRA of the samples; further studies were set up 
to dose the greyhounds with triazolam and flunitrazepam. 
The results of these studies were used to obtain 
pharmacokinetic data relating to the interaction of 
benzodiazepines and greyhounds, and to show excretion 
profiles. The latter also demonstrate the increase in 
benzodiazepine metabolites available to the receptors 
after hydrolysis, thus effectively increasing the 
sensitivity of the assay. The results were also used to 
statistically compare RIA and RRA of benzodiazepines 
enabling similarities and differences in the two assays to 
be described. The triazolam urine samples were reassayed 
after they had been stored at -20°C for 12 months. The 
results were statistically compared with those obtained 
from RRA of the samples within 2 days of collection. This 
indicated whether such conditions would cause any change 
in the benzodiazepine content of the samples. Such a 
comparison was carried out to determine that the analysis 
of stored samples reflects the true benzodiazepine 
concentration from when the sample was taken. This is 
important in cases where samples cannot be analysed within 
a few days of collection.
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3:5:5 Pharmacokinetics
During the greyhound trials only a single dose was 
given, to mimick attempted doping, rather than to carry 
out clinical trials. Therefore the pharmacokinetic data 
generated enables only two parameters to be calculated. 
These are the elimination rate constant and the 
half-life. They can be used to determine the extent to 
which it is possible to detect the presence of a 
benzodiazepine in a urine sample from a dog suspected of 
being drugged.
The results from the unhydrolysed samples were not 
used to determine pharmacokinetic data as RRA did not 
detect benzodiazepines at enough time intervals to plot 
satisfactory graphs. Before the results from the 
hydrolysed samples were graphed as a semi-log plot, they 
were recalculated so the metabolites were equated to their 
parent benzodiazepine in their affinity for the BZ-R. 
They were then used to calculate the elimination rate 
constants and half-lives for triazolam and flunitrazepam 
in greyhounds. Below, in tables 3:15 and 3:17, are 
examples of experimental data from the RRA of hydrolysed 
samples, one set for each benzodiazepine together with 
tables 3:16 and 3:18 which contain the same sets of data 
calculated in order to draw semi-log plots.
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Table 3:16 Results from Table 3:15 Calculated to Draw a 
Semi-log Plot.
Time after A t  A D u  loq a d u
10---
dosing (hrs) A t
1 1 27 . 16 1.43
2 1 22 .88 1.36
3 1 10.02 1.00
4 1 18 . 42 1.26
5 1 18 .09 1.26
6 1 7 .48 0. 87
7 1 2 . 3 0.36
24 17 3 .99 -0.6
26 2 0.98 -0 .31
- 14 6 -
Table 3:17 RRA Results from a Flunitrazepam Trial with 
the Metabolites Recalculated to Equal the
Affinity of Flunitrazepam for the BZ-R.
Time after Increase Recalculated Ur ine Final
dose (hrs) (ng/ml) (ng/ml) vo 1 . cone.
x 1.8 (ml) (uq)
1 1.5 2.7 10 0.027
2 - - - -
3 143 . 0 257 . 0 365 93 . 9
4 43 . 0 77 . 4 327 25 . 3
5 103 . 0 185 . 0 123 22 . 8
6 76 . 6 137.0 30 4 . 1
7 43 . 3 77 . 9 47 3 . 6
24 26.6 47.8 774 37 . 0
25 0.7 1.2 6 20 25 . 2
- no sample collected.
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Table 3:18 Results from Table 3:17 Calculated to Draw a 
Semi-log Plot.
Time after 
dosing (hrs)
A t A-DU logiQADU
A t
1 1 27.0 1.43
3 2 93 . 9 1. 67
4 1 25 . 3 1.40
5 1 22 . 8 1.35
6 1 4 .1 0 .61
7 1 3 . 6 0 .55
24 17 37 . 0 0.33
25 1 25 . 9 1.41
Once the above data is plotted it is possible to
calculate
kel
and S' Tables 3:19 and 3:20
summerise this data obtained from all the triazolam and 
flunitrazepam greyhound trials. These results are within 
the literature values available for triazolam and 
flunitrazepam in dogs [85,86,90].
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Table 3:19 Summary of Kinetic Data following single Oral
Dosing with Triazolam.
Trial (hr 1 ) t,^  (hrs)
01 0.53 1.29
02 0.50 1.36
03 0.49 1.39
04 0.66 1.03
05 0.64 1.09
06 0.48 1.43
07 0.67 1.02
08 0.82 0.85
09 0.74 0.93
10 0.39 1.77
11 0.39 1.77
12 0.47 1.44
13 0.67 1.03
14 0.66 1.04
15 0.53 1.31
average 0.57 ± 0.12 1.25 ±0.28
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Table 3:20 Summary of Kinetic Data following Single Oral
Dosing with Flunitrazepam.
Trial kel (hr- 1 ) t% (hrs)
16 0.91 0.76
17 0.43 1.58
18 . 1.18 0.58
19 0. 97 0.70
20 0.56 1.23
21 0. 50 1.36
22 0.41 1.67
23 0.94 0.70
24 0 . 84 0.82
25 0.76 0.91
26 0.64 1.07
0.74 ± 0.25 1.03 ±0.4
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3:5:6 Statistics
The radioreceptor assay and radioimmunoassy results 
from the analysis of unhydrolysed and hydrolysed triazolam 
urine samples are shown in tables 3:21, 3:22 , 3:23 and
3:24. A comparison of the RIA and RRA results for the 
unhydrolysed urine samples is shown in table 3:25 and 
demonstrates the lack of correlation between the two sets 
of results. The RRA results demonstrate that low 
concentrations of triazolam are excreted in the urine as 
free drug. The maximum levels seen were 30 to 35ng/ml, 
but more commonly the levels were below lOng/ml. As the 
RIA antibody will bind to any benzodiazepine-type 
compound, concentrations recorded varied from 20 to 
lOOng/ml for the early samples and 5 to 30ng/ml for the 
samples up to 30 hours after oral dosing.
Following comparison of the RIA and RRA results for 
the hydrolysed urine samples, shown in table 3:26, there 
is still a significant difference between the results up 
to 31 hours. This was unexpected as hydrolysis releases 
the conjugated triazolam metabolites thus increasing the 
amounts available to the receptor preparation. Therefore 
levels detected by RRA should approach those detected by 
RIA. However only some of the metabolites released are 
pharmacologically active and can be detected by RRA. The 
RIA antibody will bind to all the metabolites thus 
indicating higher levels of triazolam metabolites are 
present in urine samples.
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The comparison of results from RIA of the
hydrolysed and the unhydrolysed samples, are shown in 
table 3:27 and show the difference between RIA of the two 
sets of samples. In theory the two sets of results should 
be similar as the benzodiazepine antibody is reasonably 
non-specific and will bind to any benzodiazepine, its
metabolite(s ) and glucuronide conjugates. Experimentally 
however a significant difference was noted up to and 
including the 24 hour sample. The samples obtained after 
25 hours had no significant differences in their results, 
as they only contained negligible amounts of triazolam.
The significant difference in the early sets of results 
was unexpected as the Emit® antibody is specific only 
for benzodiazepines, but appears to be non-specific for 
the form of the benzodiazepine. The difference in the 
results may be due to the increased concentration of 
triazolam and metabolites present in the hydrolysed 
samples. Therefore the antibody must have some 
specificity, and not bind to conjugated glucuronide
metabolites, though it appears not to differentiate 
between the unconjugated active or inactive metabolites of 
triazolam.
The flunitrazepam RRA and RIA results for both 
unhydrolysed and hydrolysed samples are shown in tables 
3:28, 3:29, 3:30 and 3:31. Comparison of the unhydrolysed
RRA and RIA results, shown in table 3:32, reveals the 
expected lack of correlation. The highest levels recorded
TA
BL
E 
3:
27
- 158 -
rH
rH rH
cn
rH
o O
cn
cn
0 <•
rH .
Oi O' rH
£ CM
0
C/3 00
0 00 O
G CM
•H
u
p rH
£ rH0 CM
rH
O
C4 rH
0 •
•H VO rHu CM
H
73 cn
0 •
0 in rH
>» CM
rH
O 0u 0 *
73 o vO
t» 73 •X cn
G G CM
P 0
4-1 *
cn CM 00
3 0 •
cn f'. *>r
G 0
0 (4
> 3 X
O rH
73 X •
0 VO 0-
0
>»
rH *
O M3
G •
73 in cn
X *
G cn
O •
CM <r cn
0
-P *
rH cn
3 •
0 cn in
0
G X
>» 1"'-
0 *
0 CM cn
0 rH
0
o
G X
3 vO
rH O'
•H rH
o
♦H
73
0
X
0
p  •• 4-1
<  z
o  o CM
H  C/3 o
H  H XI
C/3 X 0 O X
H 0 X  ^
H  X 3 ^  *-3
<1 a rH
H  O  
C/3 U
0
>
B
A
IH
inO
O
I
u*
6 o 
73 
0 
0 Ci
cm
CMO
0
00Uto
0
73
rHI
G
m
cd
X!
0
-p
cn
0
r—Icu ■ 
£ M 
0 0
0  rH 
Cu
73 0 M 
cn 3 >>
rH 73 O 0 
M cn 
73 >>!>> i-H
X o G G 
P  73>>XI X 
X\ o 
P X
st
at
is
ti
ca
ll
ly
 
si
gn
if
ic
an
t 
re
su
lt
.
- 159 -
co
Ed
J
CU
C/3
Ed
2
H
Oi
P
P
Ed
in s
>H rH
g
O
cd 00
Q 3
>H
X
2 <D
P C
•H
Ed
X 3
H
3
Ed •rl
0
cn
C/3 3
H O
P •rl
P H-l
W cd
Ed 3
X 4-1
3
>H 01
< O
in 3
cn O
< O
X g
O 3
H CU
00 X 0)
CM Ed tsl
• • O 3
CO w 3X 4-1
Cd 0 •T^P H 3X P 3<5 rH
H X X
(4-1o
30)
XI
g32
CM
rH
O'
vO
cn
cn 3
3 0) 0)3 4J 01
0  <4-4 O
as 3 x)
c o o o o o o o o o  0 0 0 0 0 0
CM CO
CO
o 1 0 0 0 0 0 0 0 * 0 0 0 0 0 0
V O O O O O O O O O O O O O O O  
rH rH CM rH
0 >r^v0 l O O O O i n  I O O O O O  
CM CM CO CM
O v O C O O O O O O O O O O O O O  
CM in
o o o m o o o o o o o o o o o
rH
O H O O O C M i n O ' O r H O O O O O O  
O' O  - CO vO rH rH 
r-~ CO
>0'0<T'crcM*o«!jr^.-sroooooo
O  r- H  I O O  I r H i n O O O O O O  
rH rH rH H  rl
< T O O O O O O r H O 0 * O O O O O  
rH rH rH
O r H O O O O O O f ^ O O O O O O
0 0 * 0 0 0 0 0 0 0 * 0 0 0 0 0 0 0
HNCO<ft/l'ON'?in*OSOOO'OH
C M C M C M C M C M C M C O C O
TJ0)
4-1
001
CD
rHCU
- 160 -
m
w
jCu
W
w
z
H
Pd
D
Q ^-N
Cd rH
CO S
fH N
P 00
O c
CtJ
o
JH CD
ac C
Cd
X
H
c
Eb
o
01
CO C
H O
P ♦t"4
D -p
CO cd
CdOi -P
C
!* cd
<* o
CO c
CO o
<5 o
Oi €
O cd
H P
O' a. CD
CM Cd N
•  • O cd
CO Cd CHOi -P
w O ♦ fH
p H c
ca P
< 1—)
H c2 Eb
U
-P
Q-tO
U
CD
XI
63
Z
W
CD CD3 -U M
O  M-< oX <aJ TJ
CO
» • o
CM CO O o O NO CO in o O O o o o o o
rH CO rH 00 00 rH in
in rH
NO CO NO
t—1 in 1 CO CO CO NO CO NO O O o o o o o
rH rH 'ST '3- o r«. CM CM
H rH
NO NO NO CO r-* r>- NO
O CO o NO NO m CO NO NO O NO o o o o o
rH O 00 CM O' in CM CM
rH CM
CO NO NO NO
CT> O O' rH 1 o O CO NO in 1 o in o o o
rH CO NO I-' CM CM
00
r>*
00 O o O O o o NO O O o o o o o o
CO CO O NO in
rH in rH
in 00• NO •
NO NO NO r - rH rH rH CM O o o o o o o
CM O' NO CM <r NO NO
CM CO rH rH
in in
NO CM CM 'ST 'sT CM in CM <T<r o o o o o o
00 NO 00 NO CM rH CM CO
rH
in CM CM rH in in r-- 0 0 0 0 o o o o o o
CM rH rH H rH
<r 0 0 rH O 1 O O 1 o ■<r o o o o o o
0 0 rH rH
CO <r rH CO CO O O O NO rH O' o o o o o
rH CM rH rH rH rH
CM O' O O O o o O O O o o o o o o
rH
rH CO o O rH o o o O' O o o o o o o
CO nO
HNCO'^i/l'ON^Ol'ONOOO'OH
C N C N C M C M C M C M C O C O
T30)
-PO
CD
OO
<11
rH&
RA
DI
OI
MM
UN
OA
SS
AY
 
RE
SU
LT
S 
OF 
TH
E 
UN
HY
DR
OL
YS
ED
 
UR
IN
E 
SA
MP
LE
S
- 161 -
CM
rH
60
G
01
GO♦H
-ucd
U4J
G
OO
GOO
e
cd
Q*
OM
cdS-i-P
G
G
rH
|a
tp
O
G
CDXi
&
G
2
00
vO
cn
cn gGOO) 
G 4 )  tn
O <P o  sc cd -a
0' < O O O O O v f O < v O v O O v f C M t N C f  
cn XO CM CM H  CM
o I o ( \ o o o o o N O c r < j o o « < )  
<  cn cm cn "d1 n  cn cm cm cm cm cm
v O C M C f C M C M O v O c r N ' O O - c r O c n C M  
H  CM CM cn CM H  CM H  H  H  CM rl rl
O  CM O ' I c O v O O O ' O  I 00 O  00 in  rH 
cn cn CM H  r l  CM H  CM r l  H
C M O tH O O O O O O O O O O O O  
rH CO
O v O ' s T ' s T C I ' O ' C r O O O O C M O O r ^  
H  H  cn
cner>cr'vO<TOcnoooooino<r 
O  CM H  CM
O i n v O i n r ^ r H O O O O O O O O O
O  CM O' I H  <T I O O O O O O O O  
CM rH
< j < r o o < r c n o o o c n c n o o o o
o o o v o r ^ m c n o o o o o o o o o
< r v O M o < r o c M < r o o o o o o o o
CMcn^in'ON'dinMDNOOO'OH
C M C M C M C M C M C M c n c n
no 
sa
mp
le
 
co
ll
ec
te
d.
RA
DI
OI
MM
UN
OA
SS
AY
 
RE
SU
LT
S 
OF
 
TH
E 
HY
DR
OL
YS
ED
 
UR
IN
E 
SA
MP
LE
S
- 162 -
CM
rH
01
e
o♦H
-P
cdti
-PC0)O
COO
g
cda<DN
cdti
-P
♦rH
c
rH
fa
+1
cwO
Ua)
XI
ga2
00
cn
01 pU 0) V3 -P 01
O tn Os cd -a
CM'dooONOO'<jijoowo''Ocnvo 
vO M  r l  M  r l  CM r l  CM
00 IrHinO'CnHOO'vT'OOOO'O 
H  S T C N C N c n c n C N C N r H r H  rH
H c f c n H o o c n o o o o c r c o i n i N M i n c o
< T < r { n < J N N W C M C M M N C H C H C n C M
CN O  O' I 00 CT< 00 O  O  i N O r ^ O O  
CM CM rH rH cn rH H
r ^ O v O O c n r H O O O O O O O O O O  
CN LO rH rH rH O
o ' c r m o o o o o o ' c n o o o i n o o o
1/1 >0 H  H  rH rH
OT-H'>rr-vOrHa'cnooooooo 
cm cn O' cm cn cn H
o o o o > o o < r m o o o o o o o o o o
h  co oo im<r I o o o o o o o o
H
C M O c n c N c n s r o r ^ o o o o o o o
rH
O M 3 < J < J O O O O O O O O O O O
o o o o m c n c N c n ^ r o o o c n o o o o
HCMcn<rtnM)s<rin'ONooO'OrH 
CN CN CN CN CN CN cn cn
no 
sa
mp
le
 
co
ll
ec
te
d.
TA
BL
E 
3:
32
- 163 -
•J ••<S 2 U O 
H  C/3 
H  Hm x
H  C
H  Du
<* sH O w u
IP
o
«
03
Gi—1
cd
>
X
nO
tH NO
cn
u *
o in
X .cu o in
<u cn
o
fl)
D X
o cn•lH •
"D a> p»
G CM
Pd *
00
0) •
3  ■ 00 NO
01 CM
P
<D X
> <r
01 in
03 CM
i—1
a x
NO
cn NO in
CN
<u
c X
•rH • NO
p  01 •
D  03 in CM
i—1 CM
6 cu
G 0 <33
cu S3 01 X
ai in O 00
N T 1 •
g  a) 'O- cn
Ci G Ci CM
X  .H <13
•H  Cl X X
c  p (p MT
3 G •
i—i 6 P". in
fa  cd 01
CU P
•d  a G X
03 n O X
oi cd X •
> i Ci nO X
r-l -P
O -ft
P  G X
T3 G O
t>i i—1 •
X  fa in 00
G
p  *d
<u X
Ci oi 00
o >» •
<P rH 'C r-
O
oi p
-P *d X
1—1 t>r CM
G X •
oi G cn in
03 P
Pd
P X
> i O NO
cd <p *
01 CM 00
01 01
cd X
O H X
G G NO
G oi CM
€  a •
6  Pd tH cn
•H
O
•H G
•d  oi
cd oi
Pd «J
01
>
X I X  
X XN S
P P
H  X
X X
in
O
I X
rH
fa G
Ol
03
P
£
o X
*d G
<13 cd
0) O
P ♦ H
(p • X
01 •rH
ip X G
O X 00
G •rl
01 01 01
<13 0)
03 P > »
P rH
60 •d X
03 03 G
t3 Ol t)
>> •rl
rH X
iH O 01
1 p •rl
G •d X
>> G
X X
01 G 01
cd P
X
X
G
cd X I
X P X
- 164 -
after RRA were seen 2 and 3 hours after dosing though no 
flunitrazepam was detected in samples collected from 26 to 
31 hours after dosing. However RIA detected the 
benzodiazepine in samples at later time intervals, up to 
31 hours after dosing for some trials.
Comparison of the RRA and RIA results for the 
hydrolysed urine samples, shown in table 3:33, revealed a 
sgnificant difference between the results up to 31 hours. 
As RIA detects all the flunitrazepam metabolites, whether 
pharmacologically active or otherwise, it was expected 
that the increase in compounds detected by RRA following 
hydrolysis would reduce the differences in the two sets to 
an insignificant level. However this did not happen and 
demonstrates further how the RIA benzodiazepine antibody 
is relatively non-specific.
A comparison of the unhydrolysed and hydrolysed RIA 
results is shown in table 3:34. As before, no significant 
difference was expected between the two sets of results. 
However, for the majority of the time intervals there was 
a significant difference between the results. The two 
sets of results from samples collected 2 hours after 
dosing, where the highest levels of flunitrazepam and 
metabolites were found, were found not to be significantly 
different. This is likely due to the high concentration 
of pharmacologically active metabolites present in the 
unhydrolysed samples which balance any metabolites release 
by hydrolysis. For the other time intervals where there 
was no significant differences between the results, 25,
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26, 27, 30 and 31 hours after dosing, it was due to
negligble amounts of flunitrazepam detected.
The RRA results of the unhydrolysed and hydrolysed 
triazolam urine samples reassayed after twelve months at 
-20°C are shown in tables 3:35 and 3:36. Statistical 
comparison of these with the corresponding RRA results 
from analysis of the samples within two days of 
collection, shown in tables 3:21 and 3:22, are listed in 
tables 3:37 and 3:38. The comparison of the unhydrolysed 
sets of samples revealed significantly different results 2 
and 25 hours after dosing, whereas comparison of the 
hydrolysed results showed significant differences 4, 5 and 
6 hours after dosing. At all the time points where such a 
difference was seen, it was due to an overall increase in 
the amount of triazolam and metabolites detected by the 
second assay. This increase is most likely due to 
chemical breakdown of the glucuronide metabolite, which 
releases the triazolam primary metabolites. Therefore RRA 
of the samples stored for any length at time may not give 
the actual levels at the time of collection.
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3 : 6 Conclusions
Hydrolysis of the urine samples increased the
amount of benzodiazepines detected by RRA for the three 
drugs studied. In some cases benzodiazepines were only 
detected after hydrolysis indicating how extensive 
metabolism of a drug could mask its presence in a urine 
sample. This was independant of the dose. For the 
triazolam and flunitrazepam trials two dose levels were 
used and when the higher dose was given, there was little 
difference in the amounts detected both before and after 
hydrolysis compared to the lower dose. This was expected 
as the greyhounds showed no physical signs of having 
ingested a significantly higher concentration of triazolam 
or flunitrazepam. Any differences in the overall 
metabolic profiles was attributed to variation in the rate 
that each greyhound's metabolic system broke down the
benzodiazepines.
Radioreceptor assay of the triazolam and
flunitrazepam metabolites, together with the appropriate
standards, gave results which complimented those obtained
from the IC experiments. Together with the figures
5 0
for the percentage of the increase attributed to each
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metabolite, it was possible to recalculate the RRA results 
for the hydrolysed samples. Thus more accurate semi-log 
plots could be drawn in order to calculate the elimination 
rate constants and half-lives for triazolam and 
flunitrazepam in greyhounds. The kinetic results obtained 
were similar to those quoted in the literature, 
demonstrating that RRA can be used as an analytical method 
during pharmacokinetic studies. Triazolam was found to 
have a half-life of 1.25 hours ± 15 minutes which
corresponds to the major peak in each of the plots of RRA 
urine excretion data shown in figures 3:5, 3:6, 3:7, 3:8,
3:9 and 3:10. The half-life the flunitrazepam metabolites 
was calculated as being 1.03 hours ± 20 minutes which
equates with the major peaks shown in figures 3:12, 3:13,
3:14, 3:15, 3:16 and 3:17.
Conclusions drawn from the extraction experiments 
showed that the increase in analysis time was not in 
proportion to any increase in sample detection. Providing 
a blank greyhound urine sample is assayed alongside the 
actual samples, it is possible to obtain accurate results 
for the concentration of benzodiazepine in the sample. 
Any samples which contain particulate matter were 
centrifuged to ensure there is no interference with the 
BZ-receptors.
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Radioimmunoassay proved to be a suitable second 
method to confirm the presence of triazolam and 
flunitrazepam in the urine samples. Though from the 
statistical comparisons it was not possible to establish 
total correlation between RIA and RRA. Results from 
samples collected when urine concentrations of both 
benzodiazepines and their metabolites were highest had 
significant statistical differences when analysed by the 
two methods. These differences were attributed to the 
high specificity of the receptor assay for 
pharmacologically active benzodiazepine metabolites and 
the relatively non-specific BZ-antibody used in RIA. 
Therefore RIA could be used to corroborate the presence 
of benzodiazepines in urine samples, though not to confirm 
actual levels.
CHAPTER FOUR
CONCLUSIONS
A suitable radioreceptor assay has been established 
to analyse urine samples following single oral dosing of 
greyhounds. Isolation of the synaptosomal fraction was 
achieved by homogenisation and centrifugation of rat brain 
tissue. These pellets containing the benzodiazepine 
receptors were found to remain viable for up to 4 weeks 
when stored at -20°C, though the intact brain tissue 
could be stored for several months. This is probably due 
to the disruption of connective and supportive tissue 
surrounding the receptors during preparation. Thus 
allowing the 3D protein structure of the receptor to 
unfold until it no longer recognises benzodiazepines. The 
protein concentration of the pellets containing the 
receptors consistantly fell between 1 and 2mg/ml, so a 
final protein concentration of lmg/ml was used
throughout. When the actual number of receptors (B )max
and their affinity for benzodiazepines (KD ) was 
determined, the results were similar to literature values 
under the same conditions. Again protein concentrations 
of lmg/ml, or less, were used during these binding assays 
in order to obtain more accurate graphs and a better 
correlation between the points on the scatchard plot.
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It was found that the equilibrium between 
benzodiazepines and the BZ-R was established within 20 
minutes and remained stable for a further 2 hours. This 
was sufficient to assay many samples and to successfully 
separate the bound and free radioligand before disruption 
of the equilibrium begins. When these two fractions were 
separated it was by filteration and 5 x lml volumes of 
assay buffer were found to be sufficient to reduce the NSB 
to a minimum. Greater volumes of assay buffer did not 
significantly alter the levels of NSB, they only served to 
increase the separation time.
Calculation of the affinity of various 
benzodiazepines and their metabolites, the K. value,
l
demonstrated the high affinity of the parent drug for 
BZ-R. This was especially true for the short acting 
benzodiazepines, such as clonazepam, flunitrazepam, 
lorazepam and triazolam, which have the lowest values and 
therefore the highest potency. Longer acting
benzodiazepines, such as diazepam and nitrazepam, have 
higher values and lower potencies so higher doses are 
required to gain an effect. The metabolites assayed had 
higher values than their parent drug, as is expected, 
as metabolism is the way in which the body alters drug in 
order that it can be readily excreted.
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Having set up the experimental conditions, with 
standards and spiked "test" urine samples, a pilot 
greyhound study was carried out with diazepam. This was a 
siccess and showed there were no problems specific to the 
RRA of actual samples. Providing a blank urine sample is 
assayed along with possible BZ-containing samples, there 
is no requirement to carry out an extraction process. 
Hydrolysis extended to 24 hours the length of time after 
dosing during which triazolam and flunitrazepam could be 
detected in greyhound urine samples. It also increases 
the sensitivity of the assay by releasing 
pharmacologically active metabolites from their 
glucuronide conjugate thus enabling higher concentrations 
of benzodiazepines to be detected. This increase after 
hydrolysis was used in order to obtain more accurate 
pharmacokinetic data. The half-lives for triazolam and 
flunitrazepam in greyhounds obtained experimentally 
correlated with literature values for dogs.
When statistical comparisons of RRA and RIA of 
unhydrolysed and hydrolysed samples for both 
benzodiazepines were made, there were significant 
differences at all time intervals after dosing. This 
demonstrated the difference in specificity between the 
BZ-R and the BZ-antibodies, with the former having a 
higher degree of specificity than the latter. The samples 
were found to have a statistically significant increase in 
their benzodiazepine concentration when reassayed after 12 
months at -20°C. This was only seen for samples which
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had originally contained high concentrations of triazolam 
and therefore would also contain relatively high 
concentrations of triazolam glucuronide conjugates. It is 
probable that over the 12 month period these conjugates 
began to breakdown, thus increasing the concentration of 
triazolam metabolites in the samples. Such a factor would 
have to be taken in to account when urine samples are 
assayed after being stored for several months.
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RADIORECEPTOR ASSAY AND RADIOIMMUNOASSAY OF TRIAZOLAM IN 
URINE SAMPLES FROM RACING GREYHOUNDS
J.E.C. Burnett, J.s. Oliver and H. Smith
Department of Forensic Medicine and Science, University of 
Glasgow, Glasgow, G12 8QQ (U.K.)
Summary
Two complimentary assay techniques were used to 
determine triazolam levels in greyhound urine samples 
following a single oral dose. The results from the trials 
were statistically compared. The relative non-specificity 
of the benzodiazepine antibody used in radioimmunoassay 
caused a significant difference in the two sets of 
results. This was independent of hydrolysis.
Key words: Radioreceptor assay; Radioimmunoassay;
Triazolam; Greyhound urine
Introduction
Triazolam, a 1,4-benzodiazepine derivative is a 
hypnotic agent with a half-life of 2.5-3 hours. Urine 
samples collected from greyhounds following a single dose 
of this drug were assayed by radioreceptor assay (RRA) and 
radioimmunoassay (RIA) and the results compared.
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Radioreceptor assay uses receptors prepared from rat brain 
tissue. These are highly specific for benzodiazepines and 
their pharmacologically-active metabolites. [1,2]. RIA 
involves antibodies raised against benzodiazepines and 
consequently is less specific. The samples were assayed 
by both methods before and after hydrolysis using the
enzymatic method by Bloch [3], which involves 
13-glucuronidase .
Materials and Methods
The triazolam tablets (0.25 mg ) were donated by
Messrs. Upjohn Ltd. The tritiated flunitrazepam
3 . .([ H]FNZ) specific activity 81.2 Ci/mmol, was obtained
from Amersham International pic. The 13-glucuronidase, 
90,000 13-glucuronidase units/ml and 400 sulfatase 
units/ml was obtained from Sigma Chemical Company® 
U.S.A. All other chemicals were of analytical quality.
Radioreceptor assay (RRA)
Rat brain preparations were made by the Hunt [1] 
procedure but with minor adaptions due to equipment and 
scale. Approximately lg of brain tissue was homogenised 
in 5ml of 0.32M ice cold sucrose solution and centrifuged 
for 10 min at 3500g. The supernatant was removed and 
further centrifuged for 20 min at 15000g. The pellet 
formed was resuspended in 5ml of 0.025 M sodium phosphate
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buffer, pH 7.4 (assay buffer) and frozen at -20°C until
required. The receptor preparation remains viable for up 
to 6 weeks under these conditions.
The protein concentration of the preparation was estimated 
by the colourimetric method of Lowrey [4], whereby the 
protein-copper-Folin reagent complex can be measured in a 
spectrophotometer at a wavelength of 750nm.
RRA was carried out using 400ul of receptor
preparation (aproximately lmg/ml of protein), plus 50ul of
standard or sample and lOOul of [3H]FNZ,(50nCi) . The
mixtures were incubated for 45 min. at room temperature, 
and rapidly filtered through Whatman GF/B filters, under 
vacuum. The filters were washed with 5ml of assay 
buffer. The bound radiolabel-receptor complex retained by 
the filters was measured by scintillation counting for one 
minute. Incubation of the receptors with excess triazolam 
(lug/ml) enabled non-specific binding to be determined. 
Standards were prepared to cover a range from 0 to 50ng/ml 
of triazolam.
The results from the RRA were calculated by the 
method of Lund [5], where the specific binding is the 
total binding minus the binding in the assay blank. The 
standard triazolam concentrations were plotted against the 
specific binding in the zero standard divided by the 
specific binding in the standard or sample. The curve is 
linear over the range used and this enables the triazolam 
concentration in each sample to be calculated.
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Radioimmunoassay (RIA)
The samples were assayed essentially by the method 
of Robinson [6] using the antibody from the EMIT® 
benzodiazepine kit as follows. A reagent solution was 
prepared by mixing the following in equal volumes.
a) 0.05M sodium bicarbonate buffer, pH 9.0.
b) [3H]FNZ 50nCi.
c) Benzodiazepine specific antibody (4% solution).
d) A 0.125% solution of sheep serum.
500ul of this reagent was added to lOOul of sample 
or standard together with 200ul of donkey anti-sheep 
antibody (12.5% solution) and the tubes left to incubate 
overnight at 4°C. Bound and free fractions were
separated by centrifugation. 400ul of the supernatant was
added to 4ml of Ecoscint scintillant before counting.
The total amount of radiolabel available was 
estimated by the addition of 125ul of label to 675ul 
buffer, followed by incubation overnight at 4°C, 
centrifugation and removal of 400ul for scintillation 
counting. The percentage binding was estimated by the
following equation:
% binding = 1 - Ong/ml CPM x 100
Total CPM
The RIA results from the standards (0 to 50ng/ml of 
triazolam) were plotted as average counts per minute 
against triazolam concentration, from the curve the sample 
triazolam concentrations were determined.
-201-
Urine Samples
Greyhounds were given a single oral dose of 
triazolam (either one or two 250ug tablets) and urine 
samples were collected at hourly intervals for 48 hours. 
These samples were assayed before and after hydrolysis by 
RRA and RIA. Hydrolysis was carried out on 2ml of sample 
with the addition of 0.5 ml of acetate buffer (0.1M, pH 5) 
and 20ul of fl-glucuronidase from Helix pomatia. The 
mixture was incubated for 24 hours at 37°C.
Results - Data Analysis
The triazolam concentrations for each set of hourly 
samples obtained by both assay methods were compared 
statistically by the paired t-test, [7], This method is 
preferred to a means comparison as both analytical methods 
assay samples from different sources (greyhounds) which 
vary in their triazolam concentration. The paired t-test 
can deal with results from samples presented over an 
extended period as occured in this study as each greyhound 
dosing trial was carried out individually.
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Radioimmunoassay (RIA) Results for Hydrolysed versus 
Unhydrolysed Urine Samples
The comparison of results from radioimmunoassay of 
the hydrolysed and the unhydrolysed samples, are shown in 
Table 1 and determines the effect of hydrolysis on the 
RIA. Hydrolysis is known to increase the amount of 
unconjugated triazolam and its metabolites in the 
samples. In theory the two sets of results should be 
similar as the benzodiazepine antibody is reasonably 
non-specific and will bind to any benzodiazepine, its 
metabolite(s ) and glucuronide conjugates. Experimentally 
a significant difference between the two sets of results 
was noted up to and including the 24 hour samples.
Radioimmunoassay (RIA) Results for Unhydrolysed Urine 
Samples versus Radioreceptor Assay (RRA) Results for 
Unhydrolysed Urine Samples
Comparison of the RIA results, shown in Table 2, 
of the unhydrolysed urine samples and the RRA results for 
the unhydrolysed urine samples demonstrates the lack of 
correlation between these two sets of results. This was 
expected as the RRA only gives the amounts of unconjugated 
triazolam and metabolites present in the urine samples.
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Radioimmunoassay (RIA) Results for Hydrolysed Urine 
Samples versus Radioreceptor Assay (RRA) Results for 
Hydrolysed Urine Samples
Comparison of the the RIA results for the 
hydrolysed urine samples and the RRA results also for the 
hydrolysed urine samples is shown in Table 3. Greater 
correlation was expected between these sets of results as 
hydrolysis releases the conjugated triazolam metabolites 
thus increasing the amount available to the receptor 
preparation. Levels obtained for RRA theoretically would 
approach those obtained after RIA.
Discussion and Conclusions
By statistical analysis it was possible to identify 
the samples where there was a significant difference in 
the results.
There was a significant difference between RIA 
results from the hydrolysed and the unhydrolysed samples, 
(Table 1) for each of the hourly urine collections up to 
and including the seven hour sample, 
and for the 24 hour sample. The samples obtained after 
25 hours had no significant differences in their results, 
as they only contained negligible amounts of triazolam. 
The significant difference in the early sets of results 
was unexpected as the Emit® antibody is specific only 
for benzodiazepines, but appears to be non-specific for 
the form of the benzodiazepine.The difference in the
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results may be due to more triazolam and metabolites being 
detected in the hydrolysed samples, therefore the antibody 
must have some specificity for the unconjugated drug only, 
though it does not differentiate between the unconjugated 
active or inactive metabolites of triazolam.
The expected significant difference in the RIA and 
RRA results of the unhydrolysed samples (Table 2) was 
observed up to and including the 30 hour sample results. 
The results from the RRA showed a low concentration of 
triazolam was excreted in the urine as the free drug. The 
maximum levels seen were 30 to 35 ng/ml, but more commonly 
the levels were below 10 ng/ml. As the RIA antibody will 
bind to any benzodiazepine-type compound, concentrations 
recorded varied from 20 to 100 ng/ml for the early 
samples and 5 to 30 ng/ml for the samples up to 30 hours 
after oral dosing.
A greater correlation of the RIA and RRA results 
was expected following hydrolysis of the samples. However 
a significant difference was still found between the 
results up to 31 hours, (Table 3). A possible
explanation for this involves the unconjugation of the 
glucuronide metabolites, even though not all the 
metabolites released are pharmacologically active. RRA 
only detects those which are active where as the RIA 
antibody will bind to both active and inactive metabolites 
thus indicating higher concentrations of triazolam 
metabolites in urine samples.
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Figure 1 shows how hydrolysis increases the amount 
of pharmacologically active triazolam and metabolites in 
the samples, thus increasing the sensitivity of the 
radioreceptor assay. They also illustrate that the 
majority of the triazolam metabolites are to be found in 
the 2 and 3 hour samples. This ties in with the half-life 
of the drug which is between 2.5 and 3 hours in dogs, as 
previously established by Kitagawa [8 ], who studied the 
absorption, distribution and excretion of triazolam in 
dogs, rats and monkeys. He also identified the 
metabolites of triazolam found in dog and rat 
samples,[9]. The graph of the unhydrolysed samples show
the amount of free triazolam excreted in the urine. As 
expected these levels are not very high as triazolam is 
extensively metabolised by the liver to form 4-hydroxy 
triazolam and l'-hydroxy triazolam, both of which possess 
pharmacological activity. This metabolic pathway is 
described by Eberts, [10] in his paper relating to the 
disposition of triazolam in the dog. However both 
metabolites are extensively conjugated with glucuronide 
derivatives thus losing their pharmacological activity.
As hydrolysis unconjugates the derivatives found in urine, 
the amount of pharmacologically-active triazolam 
metabolites increases, as shown on the graph.
The graph also show how at 24 and 25 hours after 
oral dosing, triazolam and its metabolites are still 
detectable by RRA in urine samples. This can be
attributed to a combination of two bio-processes.
100
75
Triazolam 
con c 's 
(ng/ml)
50
25
10 20 300
Time (hours)  ^
Figure 1. RRA of urine samples immediately after 
collection.
Unhydrolysed samples - •
Hydrolysed samples - 0
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Triazolam is extensively protein-bound in the blood 
and is released slowly as the unbound fraction is 
excreted. It is this triazolam being slowly released 
which accounts for that detected in the later samples. 
There is also some evidence that triazolam undergoes 
enterohepatic circulation which can also account for its 
continued appearance in later urine samples.
To conclude it was not possible to establish any 
form of correlation between RIA and RRA. Samples 
collected when urine concentrations of triazolam and its 
metabolites were highest gave results which had 
significant statistical differences when analysed by RIA 
or RRA. These differences have been attributed to the 
high specificity of the receptor assay for 
pharmacologically active triazolam metabolites and the 
relatively non-specific antibody used in RIA.
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RADIORECEPTOR ASSAY AND RADIOIMMUNOASSAY OF FLUNITRAZEPAM 
IN URINE SAMPLES FROM RACING GREYHOUNDS
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Summary
Two complimentary assay techniques were used to 
determine flunitrazepam levels in greyhound urine samples 
following a single oral dose. The results from the trials 
were statistically compared. The relative non-specificity 
of the benzodiazepine antibody used in radioimmunoassay 
caused a significant difference in the two sets of 
results. This was independent of hydrolysis.
Key words: Radioreceptor assay; Radioimmunoassay;
Flunitrazepam; Greyhound urine
Introduction
Flunitrazepam, a 1,4-benzodiazepine derivative is a 
hypnotic agent with a half-life of 2.5-3 hours, in dog 
[1]. Urine samples collected from greyhounds following a 
single dose of this drug were assayed by radioreceptor 
assay (RRA) and radioimmunoassay (RIA) and the results 
compared.
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Radioreceptor assay uses receptors prepared from rat brain 
tissue. These are highly specific for benzodiazepines and 
their pharmacologically-active metabolites. [2,3]. RIA 
involves antibodies raised against benzodiazepines and 
consequently is less specific. The samples were assayed 
by both methods before and after hydrolysis using the
enzymatic method by Bloch [4], which involves
B-glucuronidase .
Materials and Methods
The flunitrazepam tablets (1.0 mg) were donated by
Messrs. Hoffmann-La Roche. The tritiated flunitrazepam
3 . . . .
([ H]FNZ) specific activity 81.2 Ci/mmol, was obtained
from Amersham International pic. The B-glucuronidase, 
90,000 B-glucuronidase units/ml and 400 sulfatase
units/ml was obtained from Sigma Chemical Company®
U.S.A. All other chemicals were of analytical quality.
Radioreceptor assay (RRA)
Rat brain preparations were made by the Hunt [2] 
procedure but with minor adaptions due to equipment and 
scale. Approximately Ig of brain tissue was homogenised 
in 5ml of 0.32M ice cold sucrose solution and centrifuged 
for 10 min at 3500g. The supernatant was removed and 
further centrifuged for 20 min at 15000g. The pellet 
formed was resuspended in 5ml of 0.025 M sodium phosphate
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buffer, pH 7.4 (assay buffer) and frozen at -20°C until 
required. The receptor preparation remains viable for up 
to 6 weeks under these conditions.
The protein concentration of the preparation was estimated 
by the colourimetric method of Lowrey [5], whereby the 
protein-copper-Folin reagent complex can be measured in a 
spectrophotometer at a wavelength of 750nm.
RRA was carried out using 400ul of receptor
preparation (aproximately lmg/ml of protein), plus 50ul of
3standard or sample and lOOul of [ HjFNZ,(50nCi). The 
mixtures were incubated for 45 min. at room temperature, 
and rapidly filtered through Whatman GF/B filters, under 
vacuum. The filters were washed with 5ml of assay 
buffer. The bound radiolabel-receptor complex retained by 
the filters was measured by scintillation counting for one 
minute. Incubation of the receptors with excess 
flunitrazepam (lug/ml) enabled non-specific binding to be 
determined. Standards were prepared to cover a range from 
0 to 2 0 0ng/ml of flunitrazepam.
The results from the RRA were calculated by the 
method of Lund [6 ], where the specific binding is the 
total binding minus the binding in the assay blank. The 
standard flunitrazepam concentrations were plotted against 
the specific binding in the zero standard divided by the 
specific binding in the standard or sample. The curve is 
linear over the range used and this enables the 
flunitrazepam concentration in each sample to be 
calculated.
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Radioimmunoassay (RIA)
The samples were assayed essentially by the method 
of Robinson [7] using the antibody from the EMIT® 
benzodiazepine kit as follows. A reagent solution was 
prepared by mixing the following in equal volumes.
a) 0.05M sodium bicarbonate buffer, pH 9.0.
b) [3H]FNZ 50nCi.
c) Benzodiazepine specific antibody (4% solution).
d) A 0.125% solution of sheep serum.
500ul of this reagent was added to lOOul of sample
or standard together with 2 0 0 ul of donkey anti-sheep
antibody (12.5% solution) and the tubes left to incubate
overnight at 4°C. Bound and free fractions were
separated by centrifugation. 400ul of the supernatant was
added to 4ml of Ecoscint scintillant before counting.
The total amount of radiolabel available was
estimated by the addition of 125ul of label to 675ul
buffer, followed by incubation overnight at 4°C,
centrifugation and removal of 400ul for scintillation
counting. The percentage binding was estimated by the
following equation:
% binding = 1 - Onq/ml CPM x 100
Total CPM
The RIA results from the standards (0 to 200ng/ml
of flunitrazepam) were plotted as average counts per 
minute against flunitrazepam concentration, from the curve 
the sample flunitrazepam concentrations were determined.
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Urine Samples
Greyhounds were given a single oral dose of 
flunitrazepam (either one or two lmg tablets) and urine 
samples were collected at hourly intervals for 31 hours. 
These samples were assayed before and after hydrolysis by 
RRA and RIA. Hydrolysis was carried out on 2ml of sample 
with the addition of 0.5 ml of acetate buffer (0.1M, pH 5) 
and 20ul of B-glucuronidase from Helix pomatia. The 
mixture was incubated for 24 hours at 37°c.
Results - Data Analysis
The flunitrazepam concentrations for each set of 
hourly samples obtained by both assay methods were
compared statistically by the paired t-testf [8 ]. This
method is preferred to a means comparison as both
analytical methods assay samples from different sources 
(greyhounds) which vary in their flunitrazepam
concentration. The paired t-test can deal with results 
from samples presented over an extended period as occured 
in this study as each greyhound dosing trial was carried 
out individually.
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Radioimmunoassay (RIA) Results for Hydrolysed versus 
Unhydrolysed Urine Samples
The comparison of results from radioimmunoassay of 
the hydrolysed and the unhydrolysed samples, are shown in 
Table 1 and determines the effect of hydrolysis on the 
RIA. Hydrolysis is known to increase the amount of 
unconjugated flunitrazepam and its metabolites in the 
samples. In theory the two sets of results should be 
similar as the benzodiazepine antibody is reasonably 
non-specific and will bind to any benzodiazepine, its 
metabolite(s ) and glucuronide conjugates. Experimentally 
a significant difference between the two sets of results 
was noted up to and including the 24 hour samples.
Radioimmunoassay (RIA) Results for Unhydrolysed Urine 
Samples versus Radioreceptor Assay (RRA) Results for 
Unhydrolysed Urine Samples
Comparison of the RIA results, shown in Table 2, 
of the unhydrolysed urine samples and the RRA results for 
the unhydrolysed urine samples demonstrates the lack of 
correlation between these two sets of results. This was 
expected as the RRA only gives the amounts of unconjugated 
flunitrazepam and metabolites present in the urine samples.
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Radioimmunoassay (RIA) Results for Hydrolysed Urine 
Samples versus Radioreceptor Assay (RRA) Results for 
Hydrolysed Urine Samples
Comparison of the RIA results for the hydrolysed 
urine samples and the RRA results also for the hydrolysed 
urine samples is shown in Table 3. Greater correlation 
was expected between these sets of results as hydrolysis 
releases the conjugated flunitrazepam metabolites thus 
increasing the amount available to the receptor 
preparation. Levels obtained for RRA theoretically would 
approach those obtained after RIA.
Discussion and Conclusions
By statistical analysis it was possible to identify 
the samples where there was a significant difference in 
the results.
There was a significant difference between RIA 
results from the hydrolysed and the unhydrolysed samples, 
(Table 1) for each of the hourly urine collections up to 
and including the seven hour sample, and for the 24 hour 
sample. The samples obtained after 25 hours had no 
significant differences in their results, as they only 
contained negligible amounts of flunitrazepam. Though a
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significant difference can be seen between samples taken 
at 28 and 29 hours. This is possibly due to slow release 
of the protein bound flunitrazepam. The significant 
difference in the early sets of results was unexpected as 
the Emit® antibody is specific only for benzodiazepines, 
but appears to be non-specific for the form of the 
benzodiazepine.The difference in the results may be due to 
more flunitrazepam and metabolites being detected in the 
hydrolysed samples, therefore the antibody must have some 
specificity for the unconjugated drug only, though it does 
not differentiate between the unconjugated active or 
inactive metabolites of flunitrazepam.
The expected significant difference in the RIA and 
RRA results of the unhydrolysed samples (Table 2) was 
observed up to and including the 31 hour sample results. 
The results from the RRA showed a low concentration of 
flunitrazepam was excreted in the urine as the free drug. 
The maximum levels seen were up to 790ng/ml, but more 
commonly the levels were between 10 - 50 ng/ml. As the
RIA antibody will bind to any benzodiazepine-type 
compound, concentrations recorded varied from 20 to 100 
ng/ml for the early samples and 0 to 30 ng/ml for the 
samples up to 31 hours after oral dosing.
A greater correlation of the RIA and RRA results 
was expected following hydrolysis of the samples. However 
a significant difference was still, found between the 
results up to 31 hours, (Table 3). A possible
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explanation for this involves the unconjugation of the 
glucuronide metabolites, even though not all the 
metabolites released are pharmacologically active. RRA 
only detects those which are active where as the RIA 
antibody will bind to both active and inactive metabolites 
thus indicating higher concentrations of flunitrazepam 
metabolites in urine samples.
Figure 1 shows how hydrolysis increases the amount 
of pharmacologically active flunitrazepam and metabolites 
in the samples, thus increasing the sensitivity of the 
radioreceptor assay. They also illustrate that the 
majority of the flunitrazepam metabolites are to be found 
in the first four hours after dosing, which ties in with 
the half-life of the drug. The graph of the unhydrolysed 
samples show the amount of free flunitrazepam excreted in 
the urine. As expected these levels are not very high as 
flunitrazepam is extensively metabolised by the liver to 
form N-desmethyl flunitrazepam and 7-amino flunitrazepam, 
both of which possess pharmacological activity [9]. 
However both metabolites are extensively conjugated with 
glucuronide derivatives thus losing their pharmacological 
activity. As hydrolysis unconjugates the derivatives 
found in urine, the amount of pharmacologically-active 
flunitrazepam metabolites increases, as shown on the graph.
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Figure 1 Radioreceptor Assay of Urine Samples 
for Flunitrazepam.
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To conclude it was not possible to establish any 
form of correlation between RIA and RRA. Samples 
collected when urine concentrations of flunitrazepam and 
its metabolites were highest gave results which had 
significant statistical differences when analysed by RIA 
or RRA. These differences have been attributed to the 
high specificity of the receptor assay for 
pharmacologically active flunitrazepam metabolites and the 
relatively non-specific antibody used in RIA.
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